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“I recommend biting off  more than you can chew to anyone.
I recommend sticking your foot in your mouth at any time
You wait and see when the smoke clears”
- Alanis Morissette
AbstrAct
Inflammation is evoked in defence against invading pathogens entering the body. Sometimes 
inflammation is started against harmless antigens, which leads to allergic diseases, or against self-
antigens or commensal microbiota as in inflammatory bowel disease (IBD). This thesis addresses 
treatment of  allergic disease and IBD and how immune cells are affected by the treatment.
To date, the only curative treatment available for allergy is allergen-specific immunotherapy (SIT), 
which is based on the repeated administration of  disease-eliciting allergens. The aim of  SIT is 
modification of  the allergen-specific immune response so that the allergen can be tolerated, but 
both efficacy and safety need to be improved.
The first two papers of  this thesis are focusing on different approaches to modify the allergen used 
in SIT in order to improve the treatment. In paper I we covalently coupled the immunomodulatory 
substance 1α, 25-dihydroxyvitamin D3 (VD3) to the major cat allergen rFel d 1 (rFel d 1:VD3), 
to enhance the immunomodulatory effects of  SIT. When tested in a mouse model of  cat-allergy 
it was shown that SIT with the modified allergen, rFel d 1:VD3, was effective at a lower dose 
than SIT with rFel d 1 alone. Airway hyperresponsiveness, cell infiltration and Th2 cytokines in 
bronchoalveolar lavage fluid were reduced more by rFel d 1:VD3 than by rFel d 1, indicating that 
lower allergen doses may be used in SIT. Thus both efficacy and safety could be improved.
Another way of  modifying the allergen is by changing the structure of  the protein itself. The aim 
of  paper II was to construct an altered version of  rFel d 1 with reduced number of  T-cell epitopes. 
Using error prone PCR and a phage display library, four candidate allergens were developed. They 
had reduced immunoglobulin (Ig) E-binding capacity and basophil reactivity compared to rFel d 1, 
and three of  them also had lower capacity of  inducing T-cell proliferation. These three allergens 
induced Fel d 1-specific IgG antibodies in immunised mice that had similar IgE-blocking capacity 
as rFel d 1. These properties suggest that the allergen-mutants will have a better safety profile, but 
with similar efficiency as rFel d 1, when used in SIT.
Chronic inflammatory diseases are complex and involve many different cell types and mechanisms, 
which are not yet completely understood. We studied patients with IBD as a model system for chronic 
inflammation to evaluate different cell types during resolution of  inflammation. In paper III, IBD 
patients that received anti-TNF treatment were analysed during the first six weeks of  therapy. 
There was an induction of  effector T-cells in the gut mucosa of  these patients at the same time 
as CD25+TNFRII+ helper T-cells were reduced. In peripheral blood (PB), no major changes 
in T-cell subsets were observed, but there was an indication of  changed regulatory mechanisms 
controlling antigen specific T-cell responses by anti-TNF treatment.
In paper IV we focused on the importance of  monocytes in IBD. A subset of  monocytes 
expressing high levels of  HLA-DR was shown to also express the gut homing receptor CCR9. 
Patients with IBD had a higher percentage of  HLA-DRhi monocytes in PB, and higher expression 
of  CCR9 on monocytes compared to controls. When IBD-patients were treated with granulocyte–
monocyte apheresis or corticosteroids, but not with anti-TNF treatment, the percentage of  HLA-DRhi 
in PB was reduced to the same level as controls. This may be a new subset of  monocytes important 
for inflammation in the gut and a new target for therapy.
In conclusion, this thesis presents two strategies to improve SIT by the use of  modified allergens. 
Moreover, it supports that different mechanisms are involved in different treatments of  IBD, and 
thus stresses the importance of  therapy choice.
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PCR Polymerase chain reaction
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PRR Pattern recognition receptor
RA Rheumatoid arthritis
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11 IntroductIon
1.1 tHe IMMune sYsteM
Without the immune system we would not be able to cope with invading pathogens or cell-injuries. 
This network of  different cells is our protection against the outside world and has the potential 
to kill dangerous elements threatening to harm the body. The ability to destroy foreign organisms 
also means that the immune system has the potential to harm the body by acting against harmless 
antigens or different tissues. Such misdirected hyper-reactive responses may cause allergic and 
autoimmune diseases.
One major question for the immune system is to decide whether an immune reaction should occur, 
and what type of  response that is appropriate. It has long been considered that the immune system 
distinguishes between self  and non-self, tolerating self  and initiating immune reactions to non-self. 
This model was introduced to the field of  immunology about 50 years ago [1] and has, with some 
additions to the theory, been the dogma since. This model explains much of  how the immune 
system works, but explanations of  how dangerous-self  (e.g. mutated cells) and harmless non-self  
(e.g. fetus) are handled is lacking. In 1994 Matzinger introduced the danger model, suggesting that 
the immune system reacts to danger signals, independent of  self  and non-self  [2], a compelling 
theory that has not yet won full support in the field of  immunology.
The immune system is commonly divided in two branches, innate and adaptive immunity. Innate 
immunity is the first line of  defence, which recognises pathogen associated molecular patterns 
(PAMPs) like lipopolysaccharide (LPS) of  gram negative bacterial walls or double stranded RNA 
of  viruses. The PAMPs are bound by pattern recognition receptors (PRR), which will activate an 
innate immune response upon binding [3]. The response is fast and the cells of  innate immunity 
(monocytes, macrophages, granulocytes etc) are ready to perform their actions within minutes to 
a few hours of  infection. Dendritic cells (DCs) are a link between innate and adaptive immunity. 
They sample the periphery of  the body, engulf  pathogens and engage the adaptive immunity 
against these pathogens [4]. Peptides of  the phagocytosed pathogens are presented on major 
histocompatibility complex class II (MHCII) molecules to antigen-specific T-cells, which make the 
DCs professional antigen presenting cells (APCs).
If  the innate cells are unable to clear the infection, the adaptive immune system takes over. 
Adaptive immunity is slower in action as the response is custom-made for each invading pathogen. 
The receptors of  B-cells and T-cells are unique for each cell, which leads to a vast number of  
different specificities, in contrast to PRRs, which are specific for a certain type of  PAMP. Once a 
B- or T-cell binds its specific antigen it will start dividing, generating numerous clones of  the same 
specificity to the pathogen in question. B cells will start producing appropriate antibodies and 
T-cells will perform their effector functions of  killing infected cells and providing help for driving 
and regulating the immune response. The production of  sufficient amounts of  clones takes about 
a week. The highly specific adaptive immunity is more effective in its actions than innate immunity 
and in most cases the infection will be cleared. Memory B- and T-cells are generated during the 
immune response and they circulate the body for many years, ready to start a new immune response 
upon re-infection with their specific pathogen, giving long lasting protection. Upon re-infection 
the adaptive response will be mounted in a couple of  days due to the memory cells. [3]
1.1.1 Inflammation
When a pathogen invades the body or if  an injury occurs, the response of  the immune system is 
to start inflammation. There is both sterile and septic inflammation. Sterile inflammation occurs 
when there is an injury to some tissue but without any pathogen, whereas septic inflammation 
occurs when a pathogen manages to break the barrier and invade the underlying tissue. The 
2major function of  inflammation is to recruit cells that are needed to heal the injury and clear the 
pathogen. The classic signs of  inflammation are calor (heat), rubor (redness), dolor (pain) and 
tumor (swelling), and nowadays loss of  function is often included as one of  the signs. [3]
Normal inflammation is acute and initiated by tissue-resident macrophages that phagocytose 
invading pathogens and release signalling molecules, which recruit other cells to take part in the 
immune response [3]. Neutrophils that are recruited to the site of  inflammation release the anti-
microbial contents of  their granules and phagocytose the pathogen [5]. After performing the 
effector mechanisms, neutrophils undergo apoptosis and are phagocytosed by macrophages 
to clear the inflammation and prevent tissue damage [5]. Cells of  the adaptive immune system 
are also recruited and continue the inflammation in a more effective antigen-specific manner. 
Regulatory T-cells (Treg) at the site of  inflammation are important players for constraining the 
inflammation by regulating other immune cells [6]. Sometimes the inflammation fails to clear the 
provoking stimulus. Moreover, the mechanisms regulating the resolution of  inflammation may 
become dysfunctional. These scenarios lead to sustained inflammation. The continued production 
of  cytokines, and release of  proteolytic and cytotoxic granule content, cause tissue damage and 
result in chronic inflammation.
Neutrophils undergo spontaneous apoptosis once their function at the site of  inflammation 
is fulfilled, an important mechanism for resolution of  inflammation [5]. Some pathogens have 
evolved functions that interfere with neutrophil apoptosis, which allows the infection to continue 
[7, 8]. Other pathogens can promote Tregs at the site of  inflammation [9], thus increasing their 
own survival, with continued inflammation as a consequence. Chronic inflammation may also be 
induced by increased effector and/or reduced regulatory cell mechanisms of  the host, leading to 
inability to stop the inflammation as needed.
1.1.2 Cytokines, chemokines and chemokine receptors
Cytokines are small proteins that are used by cells to communicate. The cytokines are usually 
released in response to some type of  activation and can act on the cell that produces them 
(autocrine), on cells close to the cytokine releasing cell (paracrine), and some cytokines can even 
act on cells in other parts of  the body (endocrine) [3]. The cytokines signal to the recipient cell that 
some sort of  response is appropriate, and what type of  response that should be. For instance, one 
cytokine is interferon γ (IFNγ), which is mainly released by natural-killer cells and helper T-cells 
type 1 (Th1) upon encounter of  pathogens [3]. Macrophages that are reached by the IFNγ become 
activated and kill the pathogen [10].
Chemokines are chemoattracting cytokines. They induce chemotaxis in the recipient cell that 
migrates from the circulation to the site from which the chemokine originated. The responding 
cell moves towards a concentration gradient of  the chemokine, which in the end will lead it to the 
inflammatory site. There are two major classes of  chemokines: CC chemokines (containing motifs 
with two adjacent cysteines) like CCL25, and CXC chemokines (motifs with a single amino acid 
between the cysteines) like CXCL8. Chemokine responding cells express chemokine receptors 
that are named to correspond to the type of  chemokine they bind, e.g. CCR9 for CCL25 [11]. [3]
Different tissues express different chemokines, and effector cells of  the immune system express 
different chemokine receptors, known also as homing receptors. Thus, different types of  cells 
can be recruited to the tissues where they are needed. For instance, activated DCs [12] and T-cells 
[13] express CCR7, which is a homing receptor for lymphoid organs. The CCR7 ligand CCL19 is 
constitutively expressed in thymus and lymph nodes [14]. Other examples of  homing receptors 
are CCR9 that is a gut-homing receptor as its ligand CCL25 is expressed by intestinal epithelial 
cells (EC) [15], and CCR10 that is a skin-homing receptor for CCL27, which is expressed by 
keratinocytes [16].
31.2 ceLLs of tHe IMMune sYsteM
As the immune system is very complex and in some respect involves all tissues and cells of  the 
body, only those cells that are specifically dealt with in the different papers of  this thesis will be 
described in detail. Other cell types will be briefly described and also mentioned in the context of  
the diseases where they are involved.
1.2.1 Monocytes
Monocytes are generated in the bone marrow and circulate the bloodstream a few days before 
extravasation to tissues [17]. Once they are in place in the tissue they mature to macrophages, which 
are professional phagocytes [3], or DCs [17]. Three subsets of  monocytes have been described in 
humans, CD14++CD16- “classical”, CD14+CD16++ “non-classical” [18] and an intermediate 
CD14++CD16+subset [19, 20]. The CD14++ monocytes make up about 90% of  the monocytes 
in PB and monocytes expressing both CD14 and CD16 about 8% [21]. The monocytes expressing 
both CD14 and CD16 are considered to be pro-inflammatory as they expand during inflammatory 
conditions [22-24] and have been shown to produce pro-inflammatory cytokines upon stimulation 
with LPS [25, 26]. On the other hand, the CD14++CD16+ monocytes can produce IL-10 [27], 
seemingly having a more anti-inflammatory phenotype. Both subsets of  CD16+ monocytes 
express the antigen-presentation molecule HLA-DR [27] (CD14++CD16+ showing the highest 
expression), indicating a more mature phenotype. Although monocytes are important precursors 
for macrophages and DCs, they also play a role of  their own in inflammation.
1.2.2 Dendritic cells
The DCs are key players of  the immune system, acting as sentinels that patrol the peripheral 
tissues, phagocytose antigens and subsequently migrate to lymph nodes, where the antigens are 
presented to T-cells [4]. A majority of  the DCs develop from the myeloid lineage, but there are 
also plasmacytoid DCs. The plasmacytoid DCs reside in lymphoid tissues and produce type I 
interferons in response to viruses and viral nucleic acids, which leads to the recruitment and 
activation of  many different types of  immune cells [28].
Immature DCs (iDC) reside in peripheral tissues in close vicinity to the outside world where 
pathogens are trying to enter the body. The iDCs are phagocytosing cells that also ingest soluble 
antigens by pinocytosis and receptor mediated endocytosis, with the task to raise the alarm in case 
of  invading pathogens. When a pathogen has been discovered, the iDC becomes activated, with 
subsequent maturation and migration to draining lymph nodes or the spleen. During maturation, 
the function of  the DC is shifted and it becomes a professional APC, in fact the most efficient 
APC of  the immune system. The DCs start expressing higher levels of  MHCII and co-stimulatory 
molecules such as CD40, CD80 and CD86, at the same time as it starts producing cytokines 
suitable for the defence against the type of  encountered pathogen. Once in the lymph node, the 
DC will present the antigen to T-cells that in turn will be primed and ready to perform their task. [4]
Apart from being important activators of  T-cells to mount immune responses against pathogens, 
DCs are also important regulators of  tolerance to self-antigens that the T-cells do not encounter 
during development. During non-inflammatory conditions, the DCs stay immature with low 
expression of  MHCII and co-stimulatory molecules. If  a T-cell is primed by iDCs, the lack of  co-
stimulation will induce anergy in or deletion of  that T-cell. [4]
Dendritic cells can also be differentiated in vitro from monocytes to monocytes-derived DCs 
(MDDCs), which is a good experimental system for studying DCs that are otherwise difficult 
to obtain due to their low numbers in the blood. For the in vitro differentiation, monocytes are 
cultured for 5-7 days in the presence of  granulocyte-macrophage colony stimulating factor (GM-
CSF) and interleukin (IL)-4 [29], to generate iMDDCs with a phenotype similar to iDCs. These 
cells are then ready for further experiments.
41.2.3 T‑cells
T-cells were given their name because they develop in the thymus. Progenitor cells migrate from the 
bone marrow to the thymus where they mature into naïve T-cells. In the thymus, the T-cell receptor 
(TCR) is rearranged, which gives rise to the variety of  TCR specificities. During maturation the 
T-cells also start expressing the TCR co-receptors CD4 and CD8, which will later determine what 
type of  T-cell they become. The T-cells are then selected on the basis of  their affinity for binding 
MHC:self-peptide complexes and cells that have no affinity or bind too strongly are eliminated. 
Strong binders are negatively selected whereas non-binders are eliminated when the positive 
selection of  low-affinity binders occur. This means that the surviving naïve T-cells have low-
affinity to MHC:self-peptide complex. During this selection the T-cell also stop expressing one 
of  the co-receptors. T-cells that bind to MHCI:peptide complex become cytotxic T lymphocytes 
(CTL), expressing CD8. T-cells binding to MHCII:peptide complex become T-helper cells (Th), 
including Treg, expressing CD4. [3]
1.2.3.1 Cytotoxic T lymphocytes
The only way the immune system can eradicate cell-invading pathogens is by targeting the infected 
cell itself. Most cells in the body have the ability to present intracellular peptides on MHCI. If  a 
cell becomes infected, virus/bacterium-derived peptides will be presented on MHCI to antigen-
specific CD8+ T-cells. The CD8+ T-cells are also known as CTLs because they have the ability to 
induce apoptosis in infected cells. Upon binding the specific antigen, the CTL will release cytotoxic 
granules that force the target cell to undergo apoptosis. During apoptosis the cell will destroy itself  
from within, including intracellular viruses or bacteria. Thus, further spreading of  the infection is 
prevented. The CTLs can also regulate lymphocyte numbers by inducing apoptosis through the 
Fas – Fas ligand pathway, which is an important part of  terminating an immune response. [3]
1.2.3.2 T–helper cells
Several different types of  Th cells exist that can direct immune responses to be appropriate for 
the invading pathogen. Th cells are primed when they first meet an APC that is presenting their 
specific peptide on MHCII in conjunction with co-stimulatory molecules CD80/86 that bind to 
the CD28 on the Th cell. They function as helper cells that activate CTLs or B cells and drive 
different types of  immune responses. A primed and activated Th cell becomes an effector T-cell 
that is ready to drive immune responses. [3]
The first two subsets of  Th cells to be described were Th1 and Th2 about 20 years ago [30]. For 
a long time they were the only subsets described, until recently when a Th cell subset that mainly 
expresses IL-17 was discovered and named Th17 after the hallmark cytokine [31]. In the past 
few years more subsets have been discovered like Th22 in human [32] that infiltrates the skin of  
patients with inflammatory skin disorders [33]. Also Th cells mainly expressing IL-9, Th9, were 
found in mice [34, 35] and human [36]. The different subsets develop due to expression of  specific 
transcription factors that are determinant for designating them as a separate subset, and not just a 
part of  a subset having a slightly different cytokine expression profile.
It was first found that murine Th1 cells express the transcription factor T-box expressed in T-cells 
(T-bet), and that T-bet induces expression of  the Th1 key-cytokine IFNγ [37]. Later it was also 
described in man that Th1 cells express T-bet [38]. Expression of  IFNγ prevents development of  
Th2 cells [10, 39]. Th1 cells are induced from naïve Th cells when primed in the presence of  IL-
12, through the up-regulation of  T-bet expression (Fig 1.) [38]. Functionally, Th1 cells promote 
immunity against intracellular bacteria and viruses by producing IFNγ. Macrophages, innate cell-
mediated immunity and also CTLs are activated by IFNγ [10].
Similarly it was first found in mice that Th2 cells express the transcription factor GATA binding 
5protein-3 (GATA-3), which induces expression of  IL-4 and IL-5 [40], and later the same was found 
in human Th2 cells [41]. Th2 cells have the ability to repress Th1 development [42]. Th2 cells are 
induced by IL-4 during priming and produce IL-4, IL-5 and IL-13 (Fig. 1). These cytokines are 
important for immunity against helminth parasites, as IL-4 [43] and IL-13 [44] induces isotype 
switch in B-cells leading to the production of  IgE, and IL-5 induces and promotes survival of  
eosinophils. These two actions facilitate reactions by mast cells (MC) and eosinophils that can 
secrete bioactive molecules that destroy the parasite. The induction of  IgE-production is also a 
major reason why Th2 cells are key-cells in driving allergic diseases.
Th17 cells express the transcription factor retinoid related orphan receptor γt (RORγt, the product 
of  the human mRNA RORc), which is needed for expression of  IL-17 [45]. In man, Th17 cells 
are induced by priming of  naïve Th cells in the presence of  IL-23 and IL-1β [46]. This priming is 
enforced by the presence of  transforming growth factor β (TGFβ) [45] (Fig.1). In mice, TGFβ in 
the combination with IL-6 is needed for Th17 development [47]. Th17 cells are important in the 
fight against extracellular bacteria [48, 49] and fungi [49, 50]. After the discovery of  Th17 cells, 
it has been described that Th17 rather than Th1 cells may be responsible for many autoimmune 
diseases. Th17 or IL-17 producing T-cells have been linked to diseases like psoriasis [51], rheumatoid 
arthritis (RA) [52] systemic lupus erythematosus (SLE) [53] and multiple sclerosis (MS) [54].
Figure 1. Development of  effector Th subsets and iTreg from naïve Th. The cytokines that are determining lineage 
fate during priming in human Th-cells are depicted as well as lineage-specific transcription factors. The ability to 
block other subsets is indicated.
Th9 cells are primed in the presence of  IL-4 and TGFβ and express the transcription factor PU.1, 
which induces production of  IL-9, the main hallmark cytokine of  Th9 [36]. It was shown that IL-9 
expression is increased in atopic children, and that allergic inflammation in the lungs of  mice is 
reduced in the absence of  IL-9 or PU.1 [36], suggesting a role for Th9 cells in allergy and maybe 
in asthma. Tracheal lavage from patients with allergic asthma contains IL-9 and induces expression 
6of  mucin from ECs in vitro [55], which also indicates the importance of  Th9 cells in asthma. IL-9 
is also an important growth factor for MCs that are key effector cells in allergy and asthma [56].
Induction of  Th22 cells is promoted by IL-6 and tumour necrosis factor α (TNF) [32]. No 
specific transcription factor for Th22 cells has been discovered yet and thus their status as an 
individual Th subset is still unclear. Th22 cells mainly express IL-22, and importantly they also 
express the skin homing receptor CCR10 [32]. IL-22 leads to production of  antimicrobial peptides 
from keratinocytes [57, 58]. Expression of  IL-22 is increased in psoriatic lesions [59] and patients 
with psoriasis have increased levels of  IL-22 in serum [58, 59], indicating that Th22 cells may be 
important in the pathogenesis of  psoriasis.
Most commonly Th subsets are identified by analysis of  the cytokines they secrete. In 2007, 
Acosta Rodriguez et al. [60] showed that human PB Th1, Th2 and Th17 cells could be detected 
by their surface expression of  different chemokine receptors after polyclonal stimulation in vitro. 
It was found that Th1 cells express high levels of  CXCR3 and could also express CCR6, Th2 cells 
express CCR4 in the absence of  CCR6 and Th17 cells express CCR6 in combination with CCR4. 
This observation simplifies detection of  different Th subsets as direct staining of  surface markers 
in flow cytometry can be used. The method can be applied on fresh samples and when sample 
amount is limiting, rather than using the time and material consuming in vitro stimulation of  cells 
with subsequent staining of  intracellular cytokines.
1.2.3.3 Regulatory T-cells
The Tregs are CD4+ T-cells that have the ability to regulate immune responses by inducing anergy 
and tolerance in other cells of  the immune system [3]. The existence of  Tregs was revived by 
Sakaguchi et al. [61], when they found that deletion of  CD25 in activated mouse T-cells led to 
induction of  various autoimmune diseases. There are two distinctive types of  Tregs, natural Tregs 
(nTreg) that develop in the thymus and are thought to be autoreactive [62], and inducible Tregs 
(iTreg) that acquire their suppressive phenotype in the periphery [63]. Common features of  the 
different Tregs are that they express high levels of  the high affinity IL-2 receptor subunit (CD25), in 
combination with the transcription factor Forkhead box P3 (FOXP3) and cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) [64]. Another important hallmark of  Tregs is the absence of  the IL-7R 
(CD127) [65]. It has also been suggested that more functional Tregs can be identified by analysis 
co-expression of  CD25 and TNFRII compared to only analysing the CD25hi compartment of  
Tregs [66].
Regulatory T-cells have the ability to block the functions of  effector Th subsets (Fig.1). High 
expression of  CD25 might indicate that Treg compete with other types of  T-cells for the T-cell 
growth factor IL-2, leading to apoptosis, and that this may be one mode of  their regulatory actions 
[67]. The constitutive expression of  CTLA-4 indicates that Treg have the possibility to interact 
with DCs through CD80/86. The binding of  CTLA-4 may give an inhibitory signal to the Treg 
that consequently suppresses effector T-cells [68]. This suppression may act through altering the 
interaction between effector T-cells and DCs [68]. Interaction of  CTLA-4 with CD80/86 on 
DCs can also give signals to the DC. The interaction induces the tryptophan catabolising enzyme 
indoleamine 2,3-dioxygenase, which breaks down tryptophan, an essential amino acid for T-cells 
to proliferate, and thus effector T-cell expansion is limited [68]. The FOXP3 protein represses the 
IL-2 promoter [69], which also affects the ability of  responder cells to proliferate. FOXP3 can 
physically interact with RORγt and thus inhibit Th17 development [70, 71]. The importance of  
FOXP3 to mediate regulation becomes evident in mouse and human with defects in the expression 
of  FOXP3, which leads to the severe autoimmune diseases of  scurfy mice [72] and IPEX in 
humans [73, 74]. FOXP3 is a fairly reliable marker for Treg in mice, but in human, FOXP3 is also 
transiently expressed in activated T-cells [75]. Regulatory T-cells also form long-lasting aggregates/
clusters with DCs and inhibit the maturation of  DCs [76, 77].
7Inducible Treg are generated from non-Treg CD4+CD25- effector cells by repeated antigen-
stimulation [78] and TGFβ [79, 80]. The introduction of  CTLA-4 expression in CD4+CD25- 
cells has been shown to induce cells with suppressive capacity [81]. It is believed that they are less 
stable Tregs than nTreg, but are thought to regulate antigen-specific responses upon encounter 
in the periphery [82]. Two major types of  iTreg have been described, Tr1 and Th3. Tr1 cells are 
known for their expression of  IL-10 in mice [63] and men [78], and Th3 cells for their expression 
of  TGFβ and involvement in oral tolerance in both mice [83] and humans [84].
Recently, it has been found that there are also subsets of  Treg that express Th subset-specific 
transcription factors and their specific cytokines, with remained suppressive ability. In mice, Tregs 
can start expressing T-bet during Th1 inflammation, which is necessary for the Treg to function 
under these conditions [85]. Regulatory T-cells that express T-bet and IFNγ can also be generated 
in humans, but their functions seem not to depend on these factors [86]. Another study showed 
that human iTregs expressing IFNγ developed during in vitro culture of  CD4+CD25- effector 
T-cells and similar iTreg could be isolated from tonsils [87]. An equivalent has also been found 
for Th2 cells in mice, where knockdown of  the transcription factor interferon regulatory factor-4 
(IRF4, which is linked to Th2 cells in combination with GATA-3) in Tregs leads to reduced 
suppression of  Th2 cells [88]. A population of  Treg that express signal transducer and activator 
of  transcription-3 (stat-3, a Th17 linked transcription factor in combination with RORγt) has 
been found in mice [89], where knockdown of  stat-3 led to inability to suppress Th17 cells and 
the subsequent development of  colitis. In humans, a similar population of  Tregs that expresses 
RORγt, IL-17 and the chemokine receptors CCR4 and CCR6 has been found [90].
Expression of  Th-specific transcription factors, cytokines and chemokine receptor in Tregs is 
important as this will guide the Tregs to the same site of  inflammation as the Th cells and thus 
lead to the ability of  regulating the inflammation in the tissue. These mechanisms may also provide 
some specificity in the regulation.
1.2.3.4 Plasticity between T-helper cell subsets
Allergy and allergic asthma are characterised by a Th2 milieu while IBD is characterised by a Th17, 
Th1 or Th2 milieu. In order to cure these diseases it would be desirable to break the pathologic 
cytokine milieu in favour of  a more protective cytokine milieu with other signature cytokines. 
This could be facilitated if  Th subsets were not terminally differentiated and had the ability to re-
program to another subset. This phenomenon is known as plasticity. Importantly, when getting 
older, the immune system relies more on memory CD4+ T-cells for responding to pathogens, 
which requires plasticity in order to mount a correct response [91].
Discovering more and more subsets expressing a signature cytokine raises the question if  the subsets 
are actually specific lineages or just Th cells that produce a certain cytokine at that time point, and 
later will produce another cytokine in a different tissue or inflammatory state. Indeed, it has been 
found in vitro that there is substantial plasticity between several of  the subsets. Interestingly, it 
seems like Th17 and iTreg cells are more plastic than other subsets and it is obvious that they do 
share at least TGFβ for differentiation [92, 93].
The potential for plasticity has been investigated by mapping of  methylation patterns of  cytokine 
and transcription factor genes for the different lineages. In mice, this analysis showed that signature 
cytokine genes had enhancing histone methylation as expected, but repressive histone methylation 
did not completely live up to expectation, as especially the IFNγ and IL-4 genes did not have 
repressive histone methylation in Tregs [94]. In addition, T-bet and GATA-3 genes had enhancing 
histone methylation in Th17 and Tregs, suggesting that they can be converted to Th1/Th2 cells. 
It has indeed been shown that Th17 cells can be converted to Th1 and Th2 cells in mice [95-97]. 
Regulatory T-cells can also be converted into Th17 cells both in vitro and in vivo in mice [93].
8It has also been found that Th2 cells in mice can be converted into FOXP3+ Treg with down-
regulated GATA-3 and IRF4 [98], and in man IL-12 reverses Th2 cells which leads to IFNγ and 
T-bet expressing cells with no GATA-3 expression [38]. Th1 cells seem to be a robust subset that 
does not easily develop into any other subset e.g. it was impossible to transform Th1 cells to Tregs 
[99] or Th17 cells [95] in mice in vivo. Under certain inflammatory conditions in vivo, Th1 and 
Th2 cells can be converted and start expressing the other subset’s signature cytokine in addition to 
the original cytokine profile [100].
1.2.4 Additional  immune cells
1.2.4.1 Lymphocytes and antigen presenting cells
In addition to the T-cells, there are several other types of  lymphocytes. B cells are generated in 
the bone marrow and migrate as immature B cells to peripheral lymphoid organs where they 
encounter antigens [3]. The immature B cells express IgM on the surface, which acts as the antigen 
receptor, but during development they undergo isotype switch and start expressing other antibody 
isotypes. Upon antigen encounter, the B cell is activated and develops either into antibody secreting 
plasma cells or long-lived memory B cells that respond quickly to antigen re-encounter by producing 
new plasma cells [101]. Acivated B cells can also take up antigen by receptor-mediated endocytosis, 
and act as APCs by presenting antigen-peptides on MHCII [102].
Natural killer (NK) cells are a third type of  lymphocyte that are specialised to kill target cells 
by cytolysis and secrete pro-inflammatory IFNγ and TNF. In contrast to T and B cells they do 
not carry a wide variety of  antigen-recognition receptors, but instead have inhibitory killer cell 
immunoglobulin-like receptors that bind self-MHCI molecules and keep the NK cell from killing 
host cells. Cells that become infected and down-regulate MHCI to avoid killing by CTLs are instead 
killed by NK cells that become activated in the absence of  inhibitory receptor engagement. [103]
Natural killer T-cells share surface markers and functional characteristics with both NK cells and 
T-cells. Most NKT cells express an invariant TCR that recognise glycolipid antigens presented on 
the MHCI-like molecule CD1d. Upon activation, NKT cells release immunomodulatory cytokines 
that can stimulate DCs and promote the activation of  other immune cells. [104]
Like DCs, macrophages perform a key surveillance function in the immune system. They are 
distributed in tissues and continuously search for signals of  tissue injury or invading pathogens. 
Macrophages are professional phagocytes that destroy ingested pathogens in phagolysosomes. 
Dead and dying cells are also removed by phagocytosis to maintain healthy tissues. Upon activation, 
macrophages release pro-inflammatory cytokines to induce anti-microbial mechanisms involving 
recruitment and development of  other immune cells. In addition to the phagocytosis, macrophages 
also have the ability for antigen-presentation. [105]
1.2.4.2 Granulocytes
Granulocytes got their name because their cytoplasm is filled with vesicles containing bioactive 
molecules. The neutrophils are the most abundant white blood cell and are recruited to inflamed 
tissues where they release their granule content [106] and phagocytose pathogens [107]. Neutrophils 
are short-lived, with a lifespan of  usually a couple of  hours [106]. There are several different types 
of  granules in the neutrophil that facilitate the migration to tissue where granules containing toxic 
defensins and proteases are released [5]. Another part of  the microbicidal effects of  neutrophils is 
through release of  free radicals both outside the cell and to phagosomes, which leads to formation 
of  reactive oxygen species [5, 107].
Eosinophils were given their name because their basic granule content stains intensely with the 
acidic dye eosin. The eosinophil granules contain major basic protein, eosinophil cationic protein, 
eosinophil peroxidase, eosinophil derived neurotoxin and β-glucuronidase that have anti-parasitic 
9and anti-bacterial toxicities. Eosinophils can also produce IL-4. They reside in mucosal tissues 
and are recruited to sites of  Th2-type inflammation by IL-5, the most important survival and 
differentiation factor for eosinophils. Their effector functions appear to defend against large, non-
phagocytosable organisms, but in allergic-inflammation they instead cause tissue damage. [108]
Mast cells and basophils are mainly known for their role in allergic diseases, although they play a 
very important role in the immunity to parasites. Both MC and basophils express the high-affinity 
IgE-receptor on their surface. Mast cells are found in peripheral tissues, where they can respond 
quickly to pathogens or allergens [109]. Basophils on the other hand, circulate the blood, making 
up less than 1% of  the white blood cells, and thus specific information about basophils is scarce. 
When the MC IgE-receptors are cross-linked, the granule content of  proteases and histamine 
is released within seconds and the MC start synthesising leukotrienes, prostaglandins and pro-
inflammatory cytokines, mainly of  the Th2-profile [109, 110]. Mast cells also seem able to respond 
to IL-33 as they express the IL-33R [111].
1.2.4.3 Innate lymphoid cells
Several types of  innate lymphoid cells (ILC) have been described in mice. The ILCs do not express 
any of  the lineage markers of  the known lymphoid cells and are thought to be important in parasite 
immunity and allergic diseases. The first ILC to be described was the natural helper cell that was 
found in fat-associated lymphoid clusters in the mesentery [112]. The natural helper cell expresses 
the surface markers c-Kit, Sca-1, IL-7R and IL-33R and produces large amounts of  IL-13 and IL-5 
after activation with IL-33, IL-25 and IL-2. A couple of  months later the nuocytes were described 
[113]. Nuocytes are found in mesenteric lymph nodes, spleen and bone marrow, and expand in 
response to IL-25 and IL-33.  They express c-Kit, IL-25R and IL-33R on the surface and mainly 
produce IL-13, but also IL-5. The latest subset of  ILC to be described is the innate type 2 helper 
cell [114]. Innate type 2 helper cells also expand in response to IL-25 and IL-33 and express the 
cytokines IL-13 and IL-5, but they are found in several different tissues throughout the body. In 
human, ILCs that respond to IL-25 and IL-33 with production of  IL-13 have also been described 
[115]. These ILCs were found in the lung [116], gut and PB [115].
1.2.4.4 Epithelial cells
Epithelial cells cover the surfaces of  the body, including the mucosa of  the gut and airways, and 
constitute the interface of  the internal and external milieu. The epithelium forms a physical barrier 
to substances in the environment, but also has the ability to actively participate in immunity. 
Pathogen recognition leads to release of  anti-microbial peptides to the external surface and 
cytokines/chemokines on the internal side that activate and recruit immune cells [117]. Mucus 
production is also an important host defence function of  ECs [117, 118]. In the gut, ECs interact 
with the commensal microbiota and the immune system to maintain homeostasis and to mount 
immune responses to invading pathogens [118]. In addition, ECs are an important source of  
thymic stromal lymphopoietin (TSLP), IL-25 and IL-33 that seem to be important for allergic 
inflammation [119].
1.3 ALLerGIc dIseAses
In societies with a western life style, allergies are an increasing problem where as much as 20% 
of  the population can be affected. Allergy develops when an immune response is initiated against 
otherwise harmless antigens, i.e. allergens. The most common type of  allergy is IgE-mediated 
allergy with immediate early phase reactions (EPR) that may be followed by late phase reactions 
(LPR) that occur several hours after allergen encounter [3]. Allergens can enter the body through 
the airways (e.g. cat dander, birch pollen and house dust), the gastrointestinal tract (e.g. fish, peanut), 
the skin (e.g. yeasts like Malassezia sympodialis) or by injection in the blood stream (e.g. bee venom) 
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leading to more or less severe symptoms from rhinoconjunctivitis to systemic anaphylaxis or even 
death. 
Allergic diseases are characterised by a Th2 type of  response to allergens [120]. The pathology is 
initiated when an individual is exposed to an allergen and starts producing IgE-antibodies against 
the allergen, known as sensitisation. During sensitisation, DCs take up the allergen and become 
activated under Th2-promoting conditions [121]. Subsequent presentation to allergen-specific 
naïve Th cells induces Th2 cells. The Th2 milieu promotes production of  IgE and induction 
of  eosinophils. Allergen-specific IgE is bound by high-affinity IgE receptors on tissue resident 
MCs [122]. When the allergen is encountered after sensitisation, IgE-receptors on MCs and 
basophils are cross-linked, which leads to degranulation and release of  pre-synthesised substances 
such as histamine and proteases as well as de novo synthesis of  other active substances such as 
eicosanoids and cytokines that further promote the inflammatory Th2 response [110]. Eosinophils 
are also recruited and accumulate at the site of  inflammation and become activated. The activated 
eosinophils release toxic proteins and free radicals from their granules that can cause tissue damage 
[108].
Individuals that are genetically predisposed to develop allergic disease are called atopic. Atopic 
individuals are biased to generate Th2 cells and often undergo the “atopic march”, starting with 
atopic dermatitis in infancy, which followed by food allergies and eventually development into 
airway allergies and asthma [123]. Some genes have been linked to risk of  developing allergic 
diseases. A single nucleotide polymorphism (SNP) of  the IFNγ gene has been associated with 
childhood asthma [124] and a certain haplotype in the IL-10 gene leading to decreased production 
of  IL-10 has been associated with severe asthma [125]. Asthma-related phenotypes seem to be 
associated with the protein GPRA, and the two isoforms of  the protein are differently expressed 
im healthy and asthmatic individuals [126].A bronchial hyperresponsiveness susceptibility locus on 
chromosome 5q31-q33 that contains the genes for IL-4, IL-5 and IL-13, has been identified [127]. 
Atopic dermatitis shows a strong linkage with loss-of-function mutations of  the protein filaggrin, 
which is part of  the epidermal barrier [128] and also with certain SNPs of  the α-subunit of  the 
high affinity IgE-receptor [129]. In recent years, genome wide studies have identified several genes 
and SNPs that are related to atopy [130] and asthma [131, 132]. The genetic factor is one part of  
developing allergies, but as there is not an absolute correlation with atopic parents and developing 
allergic disease, there is also an environmental factor to allergy.
The “hygiene hypothesis” initially stated that the changed living conditions during the past century, 
e.g. from a rural to an urban life style, means that there is less exposure to Th1 inducing infections 
which then leads to an increased risk of  developing allergic diseases, which are promoted by a Th2 
milieu [133]. In fact, it has been shown that growing up on a farm can be protective of  allergies [134, 
135]. In addition, there is evidence that children have an altered microbiota with less Lactobacilli 
[136] and early colonisation with Lactobacilli seems to protective from allergy [137]. A more diverse 
microflora in early life seems to prevent allergy development [138]. The gut microbiota may play 
an important part in educating and maturing the mucosal immune system as being colonised by 
Bifidobacterium species in infancy induces increased levels of  salivary secretory IgA compared to 
non-colonised infants [139]. On the other hand, it has been shown that helminthic parasites that 
induce Th2 responses are also protective of  allergic disease, perhaps through saturation of  IgE-
receptors on MCs with parasite-induced IgE [140]. In addition, the hygiene hypothesis does not 
explain why autoimmune diseases, which have a Th1/Th17 profile, have simultaneously increased 
in the same areas as allergic diseases [141]. Thus, it seems more likely that an explanation for the 
negative correlation between infections and allergy/autoimmunity is through counter-regulation 
[142]. Parasitic and bacterial pathogens, in addition to induction of  effector responses, can induce 
regulatory IL-10 [143, 144]. The IL-10 provides regulation of  allergy and autoimmunity and when 
the pathogen induced IL-10 is lost, these diseases can develop (Fig. 2).
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Allergy to inhaled allergens most often gives rise to rhinoconjunctivitis with itchy eyes and a 
congested nose. If  allergen exposure is continuous and the allergic-inflammation is not treated 
properly it may develop into asthma, which is a chronic inflammation of  the lungs. A hallmark 
of  asthma is increased airway hyperresponsiveness (AHR). Allergy to cat, which is one of  the 
most common types of  allergy in Sweden, is a major risk factor for developing asthma [145]. 
Asthma is paradoxically also characterised by IFNγ, which suggests a Th2 to Th1 shift when 
the disease progresses [120]. In children with dust mite-sensitisation and asthma, nTregs have 
been shown to have functional insufficiency with reduced ability to suppress dust mite-specific 
proliferation in vitro [146]. Other studies have shown reduced numbers and suppressive ability 
of  Tregs in paediatric asthma [147], or reduced suppressive ability of  Tregs for allergen-specific 
responses [148], suggesting that also Tregs are involved in the pathology of  allergy and asthma. 
The balance between Tr1 and Th2 cells seems to be shifted in allergic individuals where allergen-
specific Th2 cells are the dominant Th subset compared to Tr1 in healthy individuals [149, 150].
Figure 2. Counter-regulation hypothesis. 
Even if  DCs are important in priming naïve Th cells for development and Th2 cells and allergy, 
there must be some signal that tells the DC what type of  immune response to prime for. There are 
increased levels of  TSLP expressing cells in bronchial epithelium and submucosa of  patients with 
asthma [151] and TSLP is expressed in keratinocytes from atopic dermatitis lesions [152]. Human 
airway ECs produce TSLP in response to inflammatory mediators [153, 154]. TSLP can activate 
DCs to induce Th2 cells [152, 155] and activate MCs to produce Th2 cytokines [154]. Lung ECs 
have also been shown to produce IL-25 after exposure to allergens [156], and can produce IL-33 
[157]. Production of  IL-25 and IL-33 promote the expansion of  ILCs that produce IL-13 and 
IL-5 [112, 113], which promotes the allergic inflammation. Human ILCs that produce IL-13 have 
been found in nasal polyps from patients with chronic rhinosinusitis [115]. Allergic-inflammation 
may thus be initiated by ECs producing TSLP, IL-25 and IL-33 that activate ILCs and DCs for 
induction of  a Th2 response (Fig. 3) [158]. In addition, patients with allergic asthma have increased 
levels of  IL-9 and IL-13 [55] in combination with a reduced concentration of  IL-10 in the lungs [159].
12
Figure 3. Possible mechanisms for initiation of  allergic-inflammation in the lung. 
1.3.1 Allergens
What makes an allergen an allergen? That is one of  the fundamental questions when it comes to 
understanding allergy and how to treat it. Allergens are proteins or glycoproteins often delivered 
in low doses at mucosal surfaces [3]. It has been shown that the major house dust mite allergen 
Der p 1 has proteolytic activity [160] and among other actions [161] has the ability to cleave tight 
junctions between ECs in the lung [162]. Thus the allergen generates access to the lung tissue and 
can activate the ECs [163] as well as innate and adaptive immune cells. Allergens are often dimers, 
which gives them a higher probability of  cross-linking surface-bound IgE [164]. Another cause 
of  allergenicity could be by acting as an auto-adjuvant through mimicking receptors of  innate 
immunity as for the dust mite allergen Der p 2 that has structural similarity with the LPS-binding 
part of  TLR-4 [165]. It has been suggested that short ragweed pollen triggers production of  TSLP 
from epithelium through a TLR-4 dependent mechanism [166]. Aqueous birch pollen extracts 
contain bioactive lipids [167] and adenosine [168] that can act as allergy-inducing adjuvants. It is 
thus obvious that intrinsic properties of  the allergen can influence its allergenicity, although, for 
most allergens it is not known why they are allergens, and no general feature for allergenicity has 
yet been found.
1.3.2 Treatment of  allergic diseases
Currently, most of  the treatment of  allergy and allergic asthma is symptomatic with anti-histamines, 
corticosteroids and long- and short-acting β2 agonists, which lead to immediate relief  of  symptoms 
but do not cure the disease. Biological treatments targeting the Th2 profile of  the disease, such as 
omalizumab (anti-IgE) [169, 170] mepolizumab (anti-IL-5) [171, 172] and anti-IL-4Rα (blocking 
IL-4 and IL-13) [173] have been shown to improve symptoms mainly in severe asthmatics, but 
only omalizumab is approved for treatment.
There is only one type of  treatment available to date that is curative, allergen-specific immunotherapy 
(SIT) or allergy vaccination. The first SIT was carried out 100 years ago [174] and is still performed 
in a similar manner. Despite the long time frame, the mechanisms of  SIT have not been fully 
13
elucidated yet. The treatment is based on repeated administration of  disease-causing allergens with 
the aim of  modifying the allergen-specific immune response in patients so that the allergen can be 
tolerated without allergic symptoms.
It is believed that SIT leads to modulation of  the response to the allergen, from a Th2 milieu to 
a Treg response with tolerance to the allergen [175], and/or immune deviation from Th2 to Th1 
[121, 176, 177]. Indeed, production of  IL-10 and TGFβ was induced in patients receiving SIT for 
dust mite allergy [178], and IL-10 producing Treg were induced in SIT for Japanese cedar pollen 
[179]. Another important mechanism for SIT is the induction of  blocking IgG4-antibodies that 
can prevent the binding of  IgE to the allergen. In line with induction of  IL-10 by SIT, IL-10 
inhibits IgE production and instead promotes production of  IgG4 by B cells [180, 181]. Another 
effect of  SIT is that it can be protective from developing asthma [182, 183]. 
Most commonly, SIT is performed by subcutaneous injections of  the allergen extract (SCIT). 
Several studies of  SCIT have shown the induction of  allergen-specific IL-10 mediated regulation 
[184-186] or induction of  FOXP3 [187]. Typically, allergen-specific IgG4 was induced and, 
interestingly, SCIT prohibited the induction of  allergen-specific IgE during the pollen season in 
treated individuals [184, 186, 188]. The treatment protocol consists of  an initiation and up-dosing 
phase where the extract is given weekly, or more often, in increasing doses until a maintenance 
dose is reached (Fig 4.). This phase typically lasts for one to three months. Thereafter the treatment 
continues with a maintenance phase where the extract is given every 4-8 weeks, for 3-5 years. After 
the treatment is discontinued, tolerance may last for years [189].
Figure 4. Schematic view of  allergen-specific immunotherapy. At start, there is an up-dosing phase with increasing 
allergen doses. The up-dosing phase is followed by a maintenance phase where a high dose of  allergen is repeatedly 
administered for up to five years.
The long treatment period in combination with the risk of  severe side effects makes SCIT 
suboptimal. It needs to be improved both when it comes to efficiency and safety. For the past 
decades, new routes of  administration have been explored, as the risk of  granulomas at the 
injection site and the risk for anaphylactic shock are major drawbacks of  SCIT. One well-studied 
alternative is sublingual immunotherapy (SLIT). In SLIT, the extract is given in tablet form or by 
drops under the tongue every day or several times a week, typically for 3 years. Similar to SCIT, 
allergic symptoms are also decreased by SLIT [190-192] and the effects of  SLIT may last for up to 
seven years after cessation [193]. Typically, symptom scores are reduced by 30-40% by SLIT [194, 
195]. Allergen-specific IgG4 antibodies are induced [191, 192, 195-197] that have IgE-blocking 
ability [198]. FOXP3+ cells are increased in oral epithelium [198] and there is also reduced IL-4 
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production and increased IL-10 production [196]. The major advantage of  SLIT is that it has a 
better safety profile than SCIT [190].
Another alternative is intralymphatic immunotherapy (ILIT) where the allergen is injected into 
lymph nodes ensuring efficacious delivery to the APCs. Clinical trials with grass–pollen [199] and 
cat allergic patients [200] have demonstrated tolerance to the allergen after only three injections 
of  the allergen, compared to 50-60 injections in conventional SCIT. Induction of  allergen-specific 
IgG4, which was correlated to the induction of  IL-10, was demonstrated [200] as well as reduced 
levels of  allergen-specific IgE [199]. A major advantage is the small number of  injections given 
during a couple of  months. Also lower doses of  allergen can be given and the treatment seems to 
be safer than SCIT [199].
In the recent years, a fourth route of  administration has been tested, namely through the skin. 
Epicutaneous immunotherapy (EPIT) is performed by applying patches containing the allergen on 
the skin. Some promising results have been shown with EPIT for grass pollen allergy, mainly by 
reduced symptom score during the pollen season the year after EPIT [201, 202]. Further studies 
to find correct doses and treatment schedule need to be performed, as well as larger studies to 
evaluate objective parameters of  treatment efficacy.
In clinical practise, SIT is performed with allergen extracts. Unfortunately these extracts can vary 
a lot in composition and quality with significant differences between manufacturers and batches 
[203]. The use of  recombinant wild-type allergens could overcome problems with allergen extracts. 
Today allergen components serve as an improved alternative to allergen extracts for diagnosis 
of  allergic patients. A detailed sensitisation profile of  the allergic patient can be obtained with 
component-resolved diagnostics. The use of  recombinant allergen components in SIT would 
allow tailored treatment according to the patient’s sensitization profile (component-resolved 
immunotherapy) [204]. The great advantage of  recombinant allergen-based vaccines is that patients 
are treated with well-defined molecules that fulfill current quality standards for vaccine production. 
Another advantage of  SIT with recombinant allergen components is that they will not induce new 
sensitisations, which may be a problem when using whole allergen extracts [205]. However, the 
use of  recombinant allergens in SIT is still not commonly present in the clinic, although trials with 
recombinant allergens have been successfully performed and shown efficacy [206, 207].
1.3.3 Modification of  allergens
One way of  improving SIT is to modify the allergens that are used in the treatment, which can 
easily be performed on recombinant allergens to create hypo-allergens and/or allergens that are 
more effective in SIT. Many different ideas and approaches on how to increase both efficacy and 
safety of  SIT have been tested e.g. i) removal of  IgE-epitopes in the allergen, ii) disruption of  the 
allergen into smaller pieces, iii) multimerisation of  the allergen, iv) linking of  an immunomodulatory 
substance to the allergen and v) combining allergens from several sources in one molecule.
Changes in the three-dimensional structure of  a recombinant allergen can be introduced by 
mutating the allergen with polymerase chain reaction (PCR). The changed structure of  the allergen 
will decrease IgE-mediated effects of  the allergens as the IgE-binding capacity is decreased or 
lost. By changing cysteine residues of  the allergen, disulphide bonds are broken and the allergen 
becomes more linearized with destroyed IgE-binding epiopes. This approach was first applied 
to the house dust mite allergens Der f  2[208] and Der p 2 [209], which resulted in reduced IgE-
binding capacity of  the allergens. This strategy was also applied to the house dust mite allergen 
Lep d 2, where breaking all the disulphide bonds led to an allergen with lost IgE-reactivity but with 
T-cell reactivity [210]. Breaking of  the disulphide bonds in the major cat allergen, Fel d 1, reduced 
IgE-binding capacity and basophil activating capacity of  the allergen [211]. A folding variant of  
the major birch pollen allergen, Bet v 1, with disrupted secondary structure was also shown to have 
reduced ability to activate basophils with retained T-cell activating capacity [212].
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Disruption of  the allergen into smaller molecules also reduces the number of  IgE-binding 
epitopes and at the same time the risk of  immediate reactions to the allergen. Fragments of  Bet v 1 
were created with about 1000-fold reduced IgE-reactivity but retained T-cell-reactivity [213]. The 
fragments have been shown to be effective in SIT [214], leading to induction of  allergen-specific 
IgG-antibodies and reduced skin prick test to birch pollen extract [215]. Another way of  disrupting 
the allergen is by using immune-dominant peptides. Peptides are unable to cross-link IgE but still 
have T-cell epitopes, and should thus be able to modulate T-cell responses during SIT. Indeed, SIT 
with overlapping peptides of  Fel d 1 were shown to desensitise late asthmatic responses as well as 
early and late skin reactions to cat [216]. They were also shown to reduce allergen-specific T-cell 
responses in SIT [217].
Multimerisation of  allergens also disrupts the three-dimensional structure of  the allergen and 
reduces allergenicity. For birch pollen allergy, a trimer of  Bet v 1 was constructed with similar 
secondary structures as monomeric Bet v 1 but reduced ability to activate basophils and increased 
T-cell-reactivity [218]. The trimer was shown to be effective in SIT [214], with induction of  
reduced allergen-specific Th2-cytokine production in peripheral blood mononuclear cells (PBMC), 
induction of  allergen-specific IgG-antibodies and reduced skin prick test to birch pollen extract 
[215]. Even if  retained T-cell reactivity is often desired for hypo-allergens with reduced IgE-
binding, it has been shown that the majority of  the reactions to treatment occur several hours after 
injection [219], which may be LPRs due to activated allergen-specific T-cells.
All the above-mentioned ways of  allergen modification mainly leads to hypo-allergens. By attaching 
an immunomodulatory molecule to the allergen or by creating a fusion protein giving new features 
to the allergen, the efficacy of  treatment may be increased. One construct that has shown promising 
results is fusion of  the allergen with a translocation protein domain and a truncated invariant chain 
peptide (modular antigen translocation), which leads to efficient uptake and targets the allergen 
to the MHCII pathway to enhance presentation of  allergen-peptides [220]. This type of  fusion 
with Fel d 1 was shown to be effective in ILIT [200]. Linking of  CpG-containing oligonucleotides 
to the major ragweed pollen allergen induced a Th1 response and reduced AHR and cellular 
infiltration in the lungs in a mouse model of  asthma [221]. This construct was also shown to have 
effect on symptom scores when used for SIT in ragweed allergic patients [222].
Allergen can also be displayed on virus-like particles that reduce allergic symptoms when used as 
treatment in allergic mice [223]. Another adjuvant that has been coupled to rFel d 1 are carbohydrate 
particles that increase the depot-time of  the allergen [224] and reduce allergic inflammation in a 
mouse model of  cat allergy [225]. Fusion proteins of  allergen and the Fc-part of  IgG1 target the 
allergen to bind inhibitory FcγRIIb and IgE-receptors simultaneously, which initiates inhibitory 
instead of  activating signalling and results in inhibited allergic responses when used for treatment 
in allergic mice [226]. The allergen can also be targeted to the high-affinity FcγRI on APCs. A 
fusion protein of  Fel d 1 and FcγRI was shown to induce MDDCs secreting pro-inflammatory 
cytokines and IL-10 when cells from cat-allergic patients were used [227]. Though, in a later study 
it was shown that this co-priming of  MDDCs from allergic donors with this construct and TSLP 
led to enhanced Th2 responses, questioning the use of  receptor-targeted allergens in SIT [228].
Atopic individuals often become sensitised to multiple-allergens and thus develop allergic disease 
to many different sources. In Sweden, birch-pollen allergy may be the most common allergy and 
often leads to sensitisation to similar food allergens through cross-reactivity. Treatment with SIT 
for birch allergy may not be sufficient to cure the cross-reactive allergies, and they may need to 
be addressed somehow. Construction of  allergens consisting of  allergens/peptides from several 
allergenic sources could possibly be used for SIT to more than one allergy simultaneously. A 
hybrid molecule of  the four most important timothy-allergens Phl p 1/2/5 and 6 was constructed 
and showed retained IgE-epitopes with the ability to induce blocking-antibodies, but increased 
lymphoproliferative responses and release of  IL-10 and IFNγ [229]. Recently, a recombinant 
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multi-allergen chimera consisting of  a peptide from celery and one from carrot were cloned 
onto Bet v 1, and intranasal pre-treatment with the chimera prevented a Th2 response in mice 
sensitised to all three allergens [230]. Intranasal pre-treatment with a hybrid peptide composed of  
T-cell epitopes from Bet v 1 and two timothy allergens, Phl p 1 and Phl p 5, induced antibodies 
capable of  blocking basophil activation in sera from mice sensitised with the three allergens [231]. 
Pre-treatment with the peptide hybrid also suppressed cellular infiltration and Th2 cytokines in 
bronchoalveolar lavage fluid (BALF) and induced IL-10 production from splenocytes in poly-
sensitised mice [232]. A mosaic combination protein of  Der p 1 and Der p 2, where peptides of  
the two allergens were scrambled in one protein, was shown not to activate basophils from allergics 
but exhibited retained T-cell activation capacity [233]. The mosaic Der p 2/1 protein was also able 
to induce antibodies capable of  blocking the binding of  IgE from dust mite allergic patient sera.
1.3.4 Mouse models of  allergy and allergic asthma
To obtain a better understanding of  the mechanisms of  allergy and asthma, models of  allergy and 
allergic asthma can be invaluable as many studies cannot be performed in human. Mouse is the 
most common species used for allergy models. Unfortunately, the airways of  mice and human are 
different and allergy and asthma are not natural diseases of  mice. This has the implication that 
allergy is artificially induced and the models usually only resemble acute airway allergen reactions 
[234]. Also, many mouse models are based on allergy to the artificial allergen ovalbumin (OVA). 
Typically, OVA is injected two times intraperitoneally 7 to 14 days apart in combination with the 
Th2 skewing adjuvant aluminium hydroxide (alum) [235]. Protocols using allergens from relevant 
allergen sources, like cat [225] and house dust mite [236], for sensitisation may more closely 
resemble the human exposure to allergens, but are still acute models that lack the chronic features 
of  asthma.
Awareness of  differences between mice and humans is always needed. Several treatments for 
allergy have proven effective in a mouse model, but were unsuccessful when tested in human. 
Eosinophils are part of  human airway inflammation but also neutrophils seem to play an important 
role, especially in severe asthma [237, 238]. For instance, acute mouse models are often dominated 
by eosiophilic inflammation and treatment with anti-IL-5 proved to be successful. A trial with anti-
Il-5 in human reduced eosinophils numbers in blood and sputum, but had no significant effect on 
asthmatic responses [239]. More recently it has been suggested that anti-IL-5 can be effective for 
preventing asthma exacerbations in patients with refractory eosinophilic asthma [172] and helpful 
for reducing prednisone treatment in patients with prednisone-dependent asthma with sputum 
eosinophilia [171]. Thus, despite the initial disappointing results, anti-IL-5 may be effective in 
certain specific conditions of  asthma.
In order to more closely resemble the events of  human asthma, several protocols where natural 
allergens are used for induction of  chronic disease are being developed. One difficulty with 
chronic models is that tolerance is easily induced with prolonged allergen-challenge. This hurdle 
could be overcome by combined sensitisation with three different allergens [240]. Chronic models 
should imitate human asthma by showing airway remodelling and a neutrophilic component of  
the inflammation, in addition to the eosinophils. A model of  repeated house dust mite exposure 
elicited eosinophilic airway inflammation with remodelling in the lungs after seven weeks of  
exposure [241]. The model with combined allergen sensitisation also showed airway remodelling 
with increased eosinophils after eight weeks of  exposure, with increased IL-17 in the lung that 
could indicate a neutrophil component of  the inflammation even if  that was not reported [240]. 
In another model, mice were sensitised to OVA followed by exposure to aerosolised OVA for 
7-8 weeks, for development of  chronic airway inflammation [242]. The mice showed reduced 
eosinophil counts, increased amounts of  the Th1-cytokine IFNγ in BALF and lung tissue in the 
chronic phase compared to the acute. In the chronic phase of  the model there was also increased 
tissue remodelling.
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Despite all these kimitations, the mouse models are invaluable when it comes to understanding 
parts of  the disease mechanisms. Initial in vivo studies for proof  of  concepts for new asthma 
drugs could not be performed if  these models were not available [234].
1.4 AutoIMMunItY
Sometimes the immune system fails to induce tolerance towards self-antigens, which leads to an 
autoimmune reaction with the risk of  developing autoimmune diseases. In order for the immune 
system to function properly, T-cells with low-affinity for MHC:self-peptide are selected for during 
development in the thymus, and B cells with low-affinity for self  are selected for in the bone 
marrow. This means that pathogen structures and peptides that are similar or undistinguishable 
from self  can be recognised and erroneously activate the T or B cell. Normally, the self-reactive 
cells are kept in control by peripheral tolerance where constant presence of  the antigen in high 
levels in the absence of  co-stimulation and inflammatory signals lead to anergy and induction of  
Tregs or apoptosis. Self-reactive cells can be suppressed by Treg in the periphery. When these 
mechanisms fail, autoimmunity can occur. [3]
One major problem with self-antigens is that the antigen cannot be cleared, which leads to chronic 
disease once a response has been evoked. There may be many reasons for autoimmunity to occur. 
Studies have shown that, importantly, certain alleles of  the antigen presentation molecule MHCII 
are associated with several autoimmune diseases [243] and that genetic variants of  single genes can 
give rise to autoimmune disease [74, 244], but like allergic diseases, the environment also has an 
impact on autoimmunity.
T-helper 17 cells seem to be important for driving inflammation of  autoimmune nature [51, 
52, 54] and for causing inappropriate responses. Also, functional and numerical problems with 
Tregs have been proposed to be part of  the pathogenesis of  autoimmune diseases [245, 246]. 
The involvement of  T-cells in autoimmunity is further highlighted by the fact that auto-reactive 
T-cells have been found in various autoimmune diseases [247-250]. In RA, a subset of  patients 
is positive for antibodies to citrullinated protein antigens in inflamed joints, making citrullinated 
proteins possible autoantigens in RA [251]. It was also shown that the risk of  making antibodies 
to citrullinated proteins is associated with certain MHCII alleles and smoking [252, 253]. It has 
been suggested that antibodies directed towards bacterial flagellin may lead to increased intestinal 
permeability in Crohn’s disease (CD), one of  the major diseases of  IBD, [254] and that patients 
with IBD have increased levels of  IgG-antibodies directed towards commensal bacteria in the gut 
[255], indicating that CD has some traits of  an autoimmune disease.
1.5 InfLAMMAtorY boweL dIseAse
Inflammatory bowel disease (IBD) is a collective term for chronic inflammatory diseases of  the 
gastrointestinal (GI) tract. The prevalence of  IBD is about 0.4% in the population in North America 
and Europe [256]. The two major diseases of  IBD are Crohn’s disease (CD) and Ulcerative colitis 
(UC). In CD, the inflammation is discontinuous but can extend through the entire GI tract. The 
inflammation causes deep transmural ulcerations that in the long-term course of  the disease can 
develop into fistulas and cause strictures. Crohn’s disease has been linked to a Th1 profile [257, 
258]. Inflammation in UC is continuous and extends proximally from the rectum through the 
colon. Ulcerative colitis has been linked to a Th2 profile [257]. After the discovery of  Th17 cells, 
the importance of  elevated levels of  IL-17 in IBD [259] and Th17 cells is becoming more high-
lighted and investigated.
The aetiology of  IBD is unknown, but it is believed that the interplay between the innate and 
adaptive immune system and the commensal microbiota is disturbed. This could result from i) 
dysbiosis of  the commensal microbiota itself, ii) microbial pathogens or functional changes in 
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commensal microbiota, iii) genetic susceptibility of  the host and iv) insufficient regulation of  the 
immune response or enhanced activation of  inflammatory cells towards the microbiota [260].
Indeed, the microbiota in faeces of  patients with CD has been shown to significantly differ from 
that of  healthy controls [261, 262]. Differences in the microbiota that is in direct contact with the 
mucosa, and thus also in contact with the mucosal immunity, may be even more important than 
disturbed faecal microbiota. Differences in bacterial families have been found in mucosal samples 
from IBD and non-IBD controls [263, 264] where it was shown that especially commensal bacteria 
of  the Firmicutes were diminished. In particular, a reduced number of  Faecalibacterium prausnitzii 
was associated with a higher risk of  postoperative recurrence of  ileal CD [265]. In addition, culture 
of  PBMCs with F. prausnitzii induced IL-10 production from the PBMCs, suggesting that F. 
prausnitzii may have an anti-inflammatory role in the gut [265].
It has been suggested that the Mycobacterium avium subspecies paratuberculosis is a microbial 
pathogen that can induce CD as it is commonly found in gut tissue from CD patients, although it 
has not been determined if  the bacterium is causative of  disease [266]. Commensal bacteria can also 
become pathogens in IBD. Adherent-invasive Escherichia coli are common in patients with CD 
and colonise the intestinal mucosa by adhering to and invading ECs, which leads to production of  
TNF [267]. Anti-flagellin antibodies may be directed towards these E. coli. Staphylococcus aureus 
is associated with chronic rhinosinusitis, but patients with additional UC have been suggested 
to have antibodies towards S. aureus enterotoxin B in colonic mucosa, and treatment of  the 
rhinosinusitis also improves the UC scores [268]. Another normally commensal bacterium that 
can become pathogenic and is associated with IBD is enterotoxogenic Bacteroides fragilis [269].
Several genes have been linked to IBD. One of  the first genes that were found to be associated 
with susceptibility for CD is NOD2 [270]. NOD2 is an intracellular PRR that recognises muramyl 
dipeptide of  peptidoglycan from bacterial cell walls, and could possibly regulate the production 
of  defensins [271]. Paneth cells, which are major producers of  defensins, strongly express NOD2 
[272]. A decreased expression of  α-defensins in the ileum has been found in patients with CD 
[271] as well as a reduced gene copy number and expression of  β-defensins in the colon [273]. 
The decreased expression or reduced function of  the defensins leads to an impaired bacterial 
killing and thus greater opportunities for the microbiota to interact with the mucosa. Other genetic 
defects that have been linked to IBD involve genes of  the immune system. It has been found that 
IL-23R is linked to susceptibility for IBD [274]. It has also been suggested that in mice, IL-23 is 
driving inflammation of  the bowel [275]. Increasing evidence is suggesting that a Th17 milieu 
might be more important for IBD than a Th1 milieu [276]. In addition, IL-10 has also been linked 
to susceptibility for IBD [277, 278].
During homeostasis, the response of  ECs, macrophages and DCs, Tregs and Th cells of  the 
mucosa is hyporesponsive. Intestinal ECs constitute the barrier between the immune system and 
the gut microbiota and are part of  maintaining tolerance towards the microbiota. Supernatants 
from cultures of  gut ECs have been shown to condition DCs to be unable to induce Th1 responses 
[279]. Supernatants from gut ECs can also induce tolerogenic DCs [280]. In mice, intestinal DCs 
induce generation of  Treg in the presence of  TGFβ and retinoic acid [281, 282] and induce IgA 
expression in B cells [283]. Human colonic DCs have been found to promote Th2 differentiation 
when activated by Th1-inducing bacteria [279] and CD103+ DCs from mesenteric lymph-nodes 
in man have been suggested to convert naïve Th cells into FOXP3+ cells [280]. Normally, the 
response of  the mucosal immunity is to produce IgA. In contrast, it has been found that patients 
with IBD have increased levels of  IgG-antibodies directed towards commensal bacteria in the gut 
[255].
In patients with IBD, it has been suggested that the numbers of  Tregs are decreased in PB, but that 
they are increased in the inflamed mucosa [284-288]. This is similar to other autoimmune diseases 
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where increased frequencies of  Tregs are found at the site of  inflammation compared to PB [289, 
290]. Interestingly, it seems like there is increased apoptosis of  Tregs in both PB and intestinal 
mucosa of  patients with IBD [287], and this apoptosis may relate to the loss of  regulation despite 
an increased number of  Treg in the mucosa.
1.5.1 Treatment of  IBD
Usually, IBD is treated in an escalating manner. As a first line of  treatment corticosteroids are 
used. Corticosteroids have a general anti-inflammatory effect that is mediated by e.g. inhibition 
of  pro-inflammatory cytokines [291]. In UC, anti-inflammatory aminosalicylates (5-ASA) can also 
be used successfully. [292], but the effect of  5-ASA in CD is unclear and more evaluation is 
needed. The most important mechanism of  5-ASA treatment seems to be its agonistic actions on 
PPARγ [293, 294]. One effect of  5-ASA treatment is reduction of  pro-inflammatory cytokines. 
If  these initial types of  treatment are not sufficient, immunosuppressive drugs in the form of  
azathioprin or 6-mercaptopurine can be used. Both are purine analogues that can be incorporated 
in DNA and inhibit further DNA synthesis and thus also proliferation [295]. A bi-product of  
the purine analogue metabolism, 6-MP, has been shown to abrogate the memory response in 
antigen-activated T-cells after repeated antigen-stimulation in mice [296], which during the long-
term treatment leads to deletion of  T-cells that have been activated by the inflammatory process. 
Another type of  treatment for IBD is methotrexate. The most common mode of  action theory for 
methotrexate is inhibition of  purine synthesis and accumulation of  anti-inflammatory intracellular 
adenosine [297]. This can in long-term lead to less TNF and induction of  IL-10 [298]. When no 
other options are left and the inflammation can still not be kept under control, surgical resection 
and removal of  parts of  the intestine may be needed. An alternative treatment is GMA, which is a 
type of  leukapheresis that removes granulocytes and monocytes from PB.
One of  the most recent drugs to be introduced in IBD is biological therapy by targeting the cytokine 
TNF. Anti-TNF treatment generally works through two categories of  actions i) neutralisation of  
TNF and ii) reverse signalling through membrane bound TNF [299, 300]. By neutralisation of  
TNF, the direct pro-inflammatory actions of  the cytokine are blocked. Reverse signalling induces 
apoptosis and suppresses synthesis of  pro-inflammatory cytokines through resistance to LPS. 
Treatment with anti-TNF is often added to azathioprine and 5-ASA, which means that anti-TNF 
is rarely given as a sole treatment. As TNF is a pleiotropic inflammatory cytokine, varying chronic 
inflammatory diseases can be treated with anti-TNF antibodies. Blockers of  TNF are typically 
effective as treatment for RA [301] and have been approved for use in IBD.
1.6 ModuLAtIon of IMMune resPonses
When one type of  immune response is changed to another type it is referred to as immunomodulation. 
In order to cure some human diseases it would be desirable to induce immunomodulation. For 
instance the Th2 profile of  allergy and the Th1/Th17 profile of  autoimmunity could be shifted to 
a regulatory profile with tolerance of  the allergens and autoantigens. The emerging insights on the 
plasticity of  Th cells give hope that this may be possible. In addition, immunomodulation leading 
to induction of  a contra-acting immune response could also be desirable and does not require 
memory cells to re-commit to another cytokine profile.
1.6.1 Immunomodulatory substances
To modulate immune responses, some type of  intervention is needed. In SIT, tolerance is induced 
by giving increasing doses of  allergen, thus forcing modulation of  the immune response to tolerate 
the allergen. Other ways to modulate immune responses is by specific substances that can induce 
another type of  immune response than the already established. One of  the most well known types of  
immunomodulatory substances are corticosteroids, which are used for treatment of  diseases where 
the immune system needs to be kept in control e.g. IBD, SLE and asthma. Corticosteroids perform 
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their actions by binding to the glucocorticoid receptor affecting the expression of  responsive genes 
like cytokines important for generating the disease, which gives anti-inflammatory effects [291]. 
Another immunomodulatory substance that has been given attention the past few years is retinoic 
acid. Retinoic acid is naturally occurring and important for homeostasis of  the mucosal immunity, 
especially in the gut. It has been shown that retinoic acid can be used to induce tolerogenic DCs 
[280] and Treg in vitro [302] and thus could possibly be used as an immunomodulatory treatment 
agent. Another interesting immunomodulatory substance is vasoactive intestinal peptide (VIP). 
Similar to retinoic acid, VIP has the ability to induce tolerogenic DCs [303] and Tregs [304].
1.6.2 1α, 25‑dihydroxyvitamin D3
One potent immunomodulatory substance is VD3, also known as calcitriol. This steroid hormone 
vitamin is produced when ultraviolet light hits the skin and catalyses the formation of  pre-vitamin 
D3, which spontaneously isomerises and forms vitamin D3 [305]. Further, for production of  the 
biologically active form, vitamin D3 is hydroxylated in the liver into 25-hydroxyvitamin D3 and 
hydroxylated again by 1-α-hydroxylase in the kidneys into VD3 [305]. Also macrophages [306] and 
DCs [307] express the 1-α-hydroxylase and are able to produce VD3. 
Vitamin D3 binds the nuclear vitamin D receptor (VDR) that dimerises with the retinoic X receptor 
(RXR). The VDR/RXR receptor complex binds to vitamin D responsive elements (VDRE) in the 
promoter region of  genes that are responsive to VD3 [305]. Genes in the immune system, like 
FOXP3 [308], IL-10 [309] and CD14 [310] have VDREs that can be either inhibited or activated. 
Expression of  VDR has been found in many varying tissues and cells, including keratinocytes of  
the skin [311, 312], bronchial epithelium [313], T-cells [314, 315], monocytes [316], and DCs [307].
Thorough studies have shown that DCs that are treated with VD3 during in vitro differentiation 
keep a monocyte-like phenotype in both mice [317, 318] and human [319-322]. The differentiating 
DCs do not up-regulate the DC marker CD1a, they keep a low expression of  the co-stimulatory 
molecules CD40 and CD80 as well as of  MHCII, while the expression of  the monocyte marker 
CD14 is maintained. Already differentiated DCs down-regulate the expression of  co-stimulatory 
molecules and MHCII in response to VD3 and expression of  CD14 is re-induced [319, 323]. The 
VD3 induced DCs are tolerogenic and promote anergy/Treg when presenting antigens to naïve 
Th cells and also reduces T-cell proliferation in MLR [319-322].
Also T-cells can be directly regulated by VD3 [324-326]. It has been shown that IL-10 producing 
Th cells are generated in vitro in the presence of  VD3 and dexamethasone [325], that VD3 in 
combination with IL-2 induces expression of  CTLA-4 and FOXP3 on Tregs [326], and that the 
proliferation but not the suppressive function of  Treg is inhibited by VD3 [324]. Treatment with 
VD3 also leads to an inhibition of  secretion of  pro-inflammatory cytokines in T-cells [326]. It has 
also been demonstrated that VD3 inhibits the differentiation of  both Th9 and Th17 cells in mouse 
cells [327].
Another important mechanism of  VD3 is its involvement in bone and calcium metabolism. Bone 
resorption is promoted at high levels of  VD3, which makes treatment with VD3 difficult. Levels 
higher than 50nM 25-hydroxyvitamin D3 are considered optimal for maintaining bone health 
and VD3 levels, but should stay below 100nM to avoid toxicity [328, 329]. In order to reach 
immunomodulatory levels of  VD3 with oral administration, very high doses need to be given 
with risk for side effects such as hypercalcemia and increased bone resorption [305]. Most likely, 
the immunomodulatory effects of  VD3 are manifested through its local synthesis in macrophages 
and DCs.
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2 AIMs of tHe tHesIs
The overall aim of  this thesis was to evaluate the effects of  inflammation targeting therapies for 
allergic disease and IBD by investigating cellular responses and mechanisms during treatment. The 
specific objectives of  the four articles were:
Paper I: To investigate the potential of  VD3 coupled to the major cat allergen Fel d 1 as treatment 
in a mouse model of  cat-allergy.
Paper II: To develop novel hypo-allergens with reduced IgE- and T-cell reactivity using phage 
display and to test their potential for use in SIT.
Paper III: To investigate the effects of  resolution of  chronic-inflammation in IBD on different 
Th cell subsets and Treg cells as well as to explore disease mechanisms.
Paper IV: To investigate monocytes from IBD patients and to analyse their importance during 
different types of  IBD treatment.
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3 MetHodoLoGY
The methods used in the different papers are theoretically described in this section with references 
to how they were used in the papers. Each paper contains a section with detailed descriptions of  
the methods and materials.
Airway hyperresponsiveness measurements
A hallmark of  asthma is AHR. Airway hyperresponsiveness can be analysed by invasive methods, 
allowing detailed measurements of  lung function, or non-invasive methods, measuring the 
parameter PenH by whole body plethysmography. In this thesis a direct invasive method of  
AHR measurement was applied, using a small animal ventilator, FlexiVent. The AHR analysis is 
performed on sedated mice to which the ventilator is attached in the trachea. The airway response 
to increasing doses of  intravenous metacholine is recorded from computerised measurements of  
pressure and air flow. From these data the important parameters resistance and elastance can be 
calculated. Resistance is directly affected by airway narrowing, implying that this parameter can be 
linked to patient symptoms [330]. This method was used in paper I to assess how the treatments 
affected allergy like symptoms of  the lungs.
Bronchoalveolar lavage
During bronchoalveolar lavage (BAL), the lungs are flushed with a liquid to retain cells and soluble 
factors, e.g. cytokines, that are present in the lumen. These can be related to inflammation and 
disease. This method can be performed in both mice and man. In mice, the lungs are repeatedly 
flushed after sacrifice. In paper I, BAL was performed on the mice directly after AHR. The 
lungs were flushed with phosphate buffered saline, and the BALF was cytospun to glass slides 
before staining and analysis of  cell content. Differential counts of  the lung cells and cytokine 
measurements in the BALF indicate what type of  inflammation the mice exhibit after airway 
challenge.
Basophil activation test
In the basophil activation test (BAT), PB basophils are tested for reactivity and sensitivity to 
different antigens. Whole blood from allergic patients is incubated with serial dilutions of  allergen 
and then stained for the basophil marker CD203c and the degranulation marker CD63. This 
method was used in paper II for comparison of  the abilities of  the Fel d 1-mutants and rFel d 1 to 
activate basophils from cat-allergic patients and also to evaluate the ability of  antibodies induced by 
immunisation of  mice to block degranulation of  basophils. The method is a good approximation 
of  the in vivo activation of  MCs as the allergen binds to cell-bound IgE and measures ability to 
crosslink IgE receptors.
Cell culture
The possibility to culture cells in vitro is an excellent tool to test hypotheses in a controlled system 
before testing in animals in vivo, or to have a possibility to test them on human cells. Different types 
of  cell-culture have been used in paper I, II and III of  this thesis.
Monocyte derived dendritic cells were used in paper I for analysis of  the activity of  VD3 coupled 
to rFel d 1. PBMCs were separated from buffy coats and subsequently monocytes were separated 
from PBMCs by using beads binding to CD14 in magnetic activated cell sorting (MACS). 
Monocytes were cultured in serum containing medium supplemented with IL-4 and GM-CSF 
for 6 days, where the medium and cytokines were refreshed on day 3 of  culture. This leads to the 
differentiation of  iMDDCs [29], which was confirmed by analysis of  the phenotype by surface 
markers for DCs (CD11c and DC-SIGN), monocytes (CD14), co-stimulation (CD40, CD80 and 
CD86) and antigen presentation (HLA-DR/MHCII). After differentiation, the iMDDCs were 
cultured for an additional two days in serum containing medium with IL-4 and GM-CSF and 
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with different stimulations added. The effect of  the different stimulations was then assessed by 
phenotypic analysis of  the same surface markers. This method simplifies studies on DCs as they 
are scarce in PB and human tissues are tricky to obtain.
Proliferation measurements can be used for analysis of  cellular reactivity to different stimulants. 
There are different ways in how proliferation can be measured e.g. by incorporation of  3H-thymidin 
in DNA or by labelling cells with fluorescent dyes that are diluted every time the cell divides. 
These methods give an estimation of  how cells are reacting to different stimuli, but awareness of  
different mechanisms that may lead to the observed result is essential.
In paper I, splenocytes from treated mice were cultured for 6 days in the presence of  rFel d 1 
or were left un-stimulated. After 6 days of  culture samples were taken from the cell supernatants 
and frozen at -80oC for later measurement of  cytokines. Then, for the last 18h of  culture, 
3[H]-thymidine was added. After culture the cells were harvested onto a filter and 3H-thymidin 
incorporation in DNA of  proliferating cells was measured by a scintillation counter. In paper 
II, PBMCs from cat-allergic patients were put in proliferation culture with rFel d 1, the different 
Fel d 1-mutants or left un-stimulated to investigate the reactivity to the mutants. In paper III, 
PBMCs from IBD patients before and after anti-TNF treatment were put in proliferation culture 
with rFel d 1, a pollen mix made from commercially available pollen extracts, influenza antigen 
or left un-stimulated. At the same time, the cultures were supplemented with either anti-IL-10, 
which blocks the activity of  IL-10, or soluble TGFβ receptor II, which blocks the activity of  
TGFβ. From some cultures, CD25+ cells were depleted by MACS using beads binding CD25. 
This allowed for analysis of  the differences in the patients’ reactivity before and after treatment 
and if  different types of  regulatory mechanisms were acting at these time points. Cultures for 
testing the suppressive ability of  CD25+ Tregs were also performed in paper III. CD4+CD25+ 
Treg, CD4+CD25- effector T-cells and CD4- cells containing monocytes as APCs were separated 
from PBMCs, and put together at different ratios, and proliferation was measured. 
Cytometric bead array
Cytometric bead array is a bead based assay that can be used to measure cytokines in solution 
using a flow cytometer. Beads with cytokine-specific antibodies are incubated with the fluid that 
will be analysed and a second cytokine-specific antibody conjugated to a fluorescent colour is used 
for detection of  the amount of  cytokine. The beads can be separated in the flow cytometer by 
intensity of  one or more fluorescent colours according to which system is used. Each cytokine 
bead has a specific size/colour combination which makes this possible. This method allows for 
analysis of  several cytokines simultaneously. In addition, the system requires small volumes of  
fluid (compared to ELISA, see below), which makes it useful when a limited amount of  fluid is 
available. Cytokines in proliferation culture supernatants and BALF were analysed by this method 
in paper I.
Enzyme-linked immunosrobent assay (ELISA)
ELISA is an assay that can be used to determine the content of  different compounds in fluids. 
Usually, a primary antibody towards the compound of  interest is attached to the wells of  an 
ELISA-plate, the plate is then incubated with the fluid to be analysed and finally a secondary 
antibody towards another part of  the compound is added. The secondary antibody is conjugated 
to an enzyme that catalyses the conversion of  a colourless substrate to a coloured product that can 
be detected in a spectrophotometer. The ELISA is very sensitive and depending on the compound 
measured, as little as pg/ml can be measured.
An ELISA method was used in paper I and II for analysis of  different subclasses of  antibodies 
towards Fel d 1 in serum and BALF of  mice. The ELISA-plates were coated with rFel d 1, 
incubated with serum/BALF and analysed with anti-Ig subclass antibody conjugated to alkaline 
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phosphatase. For analysis of  IgE, which is present at much lower concentrations than the other 
Ig subclasses, the ELISA plates were coated with anti-IgE antibody, incubated with serum and 
analysed by rFel d 1 indirectly labelled with alkaline phosphatase. The ability of  the antibodies to 
block IgE-binding was assessed using ELISA where plates were coated with rFel d 1, incubated 
with mouse serum and then incubated with pooled human serum from cat-allergic patients, or 
the human serum was incubated with rFel d 1/Fel d 1-mutants overnight prior to addition to the 
rFel d 1-coated plate, before analysis with an antibody towards human IgE.
Expression and purification of  recombinant proteins
One major problem with allergen extracts used for SIT is that they may exhibit varying allergen 
content and quality between different suppliers and batches [203]. An option to solve this is to 
use recombinant allergens, providing pure allergens with controlled content. For production 
of  recombinant proteins used in this thesis (paper I and II), different strains of  E. coli were 
transformed with a plasmid encoding rFel d 1 [331] or the Fel d 1-mutants [332] with a 6xHis-tag. 
For production of  protein, addition of  isopropyl thiogalactoside activates the expression of  the 
protein encoded by the plasmid.
After expression, the protein is found in the cytoplasm, either in soluble form or as inclusion bodies 
that have to be solubilised. For purification of  the protein, the bacteria are pelleted and frozen 
before sonication to break the cell walls. Insoluble proteins were solubilised with 6 M guanidine-
HCl. Proteins are then affinity purified by immobilised metal chelate affinity chromatography 
with Ni2+-ions that bind the 6xHis-tag of  the protein. To re-fold the protein, dialysis against 
phosphate buffered saline is performed and the protein is subsequently purified by size exclusion 
chromatography on a gel-filtration column to separate multimers and monomers. Multimers are 
subjected to further denaturing, refolding and gel-filtration steps to obtain monomers followed 
by purification of  monomers by ion exchange chromatography to obtain highly purified proteins. 
Finally, the quality of  the protein is analysed. Separation in gel-electrophoresis reveals the purity 
of  the protein and can give information on monomeric and multimeric content. The LPS content 
in the protein solution is determined by limulus amebocyte lysate endochrome assay, an essential 
analysis to perform as the protein is expressed in E. coli. Protein concentration can be determined 
by bicinchoninic acid assay.
ImmunoCAP System
This is a diagnostic method to determine allergen-specific IgE-antibodies in serum. In paper III, 
IgE antibody levels to cat, birch and timothy in serum were measured and a value ≥0.35 kU/L was 
considered positive.
Magnetic activated cell sorting (MACS)
MACS is used for separation of  cells employing magnetic beads coated with antibodies to lineage 
specific cell markers. Cells can be separated “positively” by beads binding to the cell of  interest 
or “negatively” by beads binding to all cells but the cell of  interest. Once the cells have been 
incubated with the magnetic beads, cells are separated by passing the cells over a magnetic column 
that will bind the magnetic beads. This method allows fast separation of  cells, but the purity of  the 
separation can sometimes be insufficient. In paper I and IV, monocytes were positively separated 
from PBMCs by anti-CD14 conjugated beads. In paper III, CD4+ T-cells were negatively 
separated from PBMCs and CD25+ cells were positively depleted from CD4+ T-cells.
Mouse model of  allergy to cat
In paper I, a mouse model of  allergy to cat was employed [225]. This is an acute type of  allergy 
model where BALB/c mice are first sensitised by three subcutaneous injections of  rFel d 1 
adsorbed to alum every second week. After 11 days, the mice are challenged once daily for three 
25
days with cat dander extract intranasally and one day after the last challenge they are sacrificed 
(Fig. 5). The 11 day window between sensitisation and challenge gives the opportunity to treat 
the allergy-like sypmtoms. In paper I, mice were treated with rFel d 1 or rFel d 1:VD3. Airway 
hyperresponsiveness can be measured at the time of  sacrifice and heart blood, spleen, BAL and 
lungs can be taken for subsequent analyses. In paper II, mice were treated with rFel d 1, or the 
Fel d 1-mutants 3.4.7 or 6.7.1, but only analysis of  serum antibodies was employed.
Figure 5. Schematic outline of  the mouse model for cat allergy. Numbers indicate day of  action.
To evaluate the antibody profile induced by new allergy-vaccine preparations, mice can be 
immunised with the allergy-vaccine. Mice are injected with the allergy-vaccine every second week, 
in total three to four times, using a higher dose than for sensitisation. Blood is drawn before and 
during the course of  immunisations from the tail artery and upon sacrifice by heart puncture, to 
measure antibody titers. In paper II, mice were immunised with the Fel d 1-mutants or rFel d 1.
Multi-colour flow cytometry
Flow cytometry is a method that can be used for analysis of  surface markers on cells, intracellular 
proteins, cytometric bead array, sorting of  cell-populations (fluorescence activated cell sorting, 
FACS), and other analyses that are not discussed here. The basic principle of  the technique is that 
antibodies to cellular-markers are labelled with a fluorescent marker. Cells are then incubated with 
these antibodies that will bind to their target, allowing both detection and quantification by analysis 
in a flow cytometer.
In the flow cytometer, the liquid containing the cells is formed into a stream with single cells by the 
pressure of  the sheath fluid. The stream passes through an array of  lasers that excite electrons of  
the fluorescent makers. The light that is emitted when the electron falls back to the ground state 
is detected by different photomultiplier tubes (PMTs) that register a signal from each cell. There is 
a separate PMT for each fluorescent marker. The emitted light is directed to the correct PMT by 
an array of  mirrors and filters (Fig. 6). Cells are also analysed for their size and granularity. Light 
that goes straight through cells (forward scatter, FSC) gives information of  cell size and light that 
is scattered 90° (side scatter, SSC) from the ingoing light gives information about cell granularity. 
The FSC and SSC are also measured by PMTs.
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Figure 6. Principle of  a flow cytometer. 
For cell-sorting (FACS), the stream of  cells is passed through a nozzle that form drops with 
single cells. The drops are electrically charged dependent on instrument settings for sorting. When 
passed through an electric field, the charged droplets will be directed from the stream to collection 
tubes. This method of  separation of  cellular subsets gives a high purity of  sorted cells, but is time 
consuming. Using a combination of  pre-sorting with MACS and subsequent FACS increases the 
purity of  the MACS and speeds up the FACS.
Flow cytometry was used for analysis of  surface markers and intracellular transcription factors in 
paper I, III and IV. By using eight different colours at the same time, eight different markers could 
be anlaysed on single cells. Thus detailed information on cell type/subclass as well as activation 
state could be obtained from the same sample.
Phage display
Phage libraries have various applications, but common for them all is that they contain phages 
carrying plasmids encoding a multitude of  unique proteins. To select the plasmids encoding a 
protein of  interest, bacteria transfected with phages are grown to amplify the phage library. The 
phages express the protein they encode for on the surface. Phages expressing a protein with 
desired properties are then isolated through a selection process referred to as bio-panning. The 
bio-panning may be performed by ELISA and after elution from the plate, the phages are once 
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again allowed to transfect bacteria. The amplification and selection process may be carried out for 
several rounds. Clones of  bacteria transfected with phages containing the gene for a protein with 
desired properties are finally cultured for expression of  the protein.
In paper II, Fel d 1 was mutated by error-prone PCR. This method allows for an option to alter 
proteins without having extensive information about the structure and function of  the protein. 
The mutated Fel d 1 was used to create phage display libraries and bio-panning for binding to 
IgE from cat-allergic patients was used to select Fel d 1 mutants with IgE-binding capacity. The 
bio-panning was carried out in several rounds with increasing stringency that allowed only the 
strongest IgE-binding Fel d 1-mutants to be selected for.
qPCR
To measure the expression of  mRNA in different cell types, quantitative (q) PCR can be used. 
First, total mRNA of  the cells to be analysed is purified. The mRNA is then reverse-transcribed 
to cDNA in a PCR reaction that contains random primers. Once cDNA is obtained the qPCR can 
be performed. The PCR reaction, comprising the normal denaturation, annealing and elongation 
steps, is carried out with a reaction mix containing a dye that binds to dsDNA and emits light only 
when bound. After each elongation round, the amount of  light from each reaction is recorded. 
The amount of  light recorded is proportional to the amount of  DNA synthesized. Thus the 
amount of  mRNA encoding the protein of  interest and to which the specific primers in the PCR 
reaction mix is directed can be quantified in the original sample.
This method quantitates the amount of  mRNA in each sample either by an internal standard curve 
that gives a concentration of  mRNA, or by relating the target mRNA in each sample to mRNA 
from a reference gene that should be expressed equally by all cells. In paper III and IV, qPCR was 
used to analyse mRNA for different cytokines and transcription factors in PBMCs and monocytes, 
respectively.
UV circular dichroism spectroscopy
In a CD-spectrum analysis, the difference in absorption of  left and right circular polarised light 
by a protein is measured and the secondary structure of  the protein is estimated. Helical structure 
and sheets absorb differently at different wavelengths of  light passing through a protein solution. 
Thus α-helices, β-sheets, β turn and random coil parts of  protein give distinct CD absorption 
signatures and the amount of  each type of  structure in the molecule can be estimated. CD 
spectrum analysis is useful for comparing the secondary structure of  different proteins, without 
crystallisation. In paper II, the method was used to compare the secondary structure of  rFel d 1 
and the Fel d 1-mutants.
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4 resuLts And dIscussIon
Common for all the projects in this thesis is that they relate to some form of  inflammation. In 
paper I and II, different approaches to improve SIT that can cure the acute inflammation of  
allergy were investigated whereas paper III and IV are focused on chronic inflammation of  the 
gut and how that inflammation may be healed by anti-inflammatory treatment.
4.1 feL d 1:Vd3 In IMMunotHerAPY
In paper I, VD3 was covalently coupled to rFel d 1 (rFel d 1:VD3) using a Mannich formaldehyde 
reaction [333], to create a variant of  Fel d 1 that could be potentially more efficient in SIT. It has 
long been known that VD3 has immunomodulatory effects that lead to induction of  tolerogenic 
DCs [319-322] and Tregs [325, 326]. As a first test of  the rFel d 1:VD3, we analysed the ability 
to induce up-regulation of  CD14, on the surface of  MDDCs. At equimolar concentrations, 
rFel d 1:VD3 was as potent as VD3 alone to up-regulate CD14. This result confirmed that the 
coupled VD3 was still in its active form.
Previous to this study it had been shown that co-administration of  VD3 with OVA in a SIT 
model led to a more efficient SIT in mice [334]. We hypothesised that covalent coupling of  
VD3 to rFel d 1 could increase the efficacy even more as the immunomodulatory effect exerted 
by VD3 will affect the same APC that will present Fel d 1 to allergen-specific T-cells. The 
importance of  covalent coupling of  the immunomodulator to the antigen to modulate the type 
of  immune response that is induced was recently shown by Kamath et al [335]. Covalently 
coupled adjuvant induced strong immune responses, whereas co-administration also induced 
a population of  APCs that had not taken up the adjuvant and were non-activated.This led to a 
much weaker immune response. The effects of  rFel d 1:VD3 were evaluated in a mouse model 
of  cat allergy [225]. Mice were sensitised to Fel d 1 and treated with rFel d 1:VD3 or rFel d 1 
alone in two doses (10 and 5 μg) and different parameters important for allergy were evaluated.
First, the effects of  SIT on the airways of  treated mice were analysed. Airway hyperresponsiveness 
was reduced by treatment with both rFel d 1:VD3 and rFel d 1, compared to untreated mice. 
At the higher treatment dose there was no difference in efficiency between the two treatments, 
but at the lower dose rFel d 1:VD3 was as efficient as the higher dose whereas rFel d 1 was not. 
The ability of  SIT to reduce AHR, a key feature of  asthma, is important in order to prevent the 
development of  asthma.
Infiltration of  inflammatory cells, especially eosinophils, in BALF was not increased compared 
to control in mice treated with rFel d 1:VD3 at either dose, while treatment with rFel d 1 alone 
could not prevent cell infiltration (Fig. 7). Also, the level of  IL-5 in BALF was more potently 
reduced by rFel d 1:VD3 treatment than rFel d 1 treatment. These results indicate that the 
inflammation of  the lungs was more potently inhibited by rFel d 1:VD3 treatment. Taken 
together, evaluation of  the treatment effects on lung indicated that rFel d 1:VD3 might be more 
efficient than rFel d 1 when the treatment dose is decreased.
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Figure 7. Cellular content in bronchoalveolar lavage was counted and cells were collected and resuspended in PBS 
before cytospun to glass slides. The glass-slides were stained with hematoxylin and eosin and for differential counts 
a minimum of  300 cells/slide were counted. 
It is believed that one part of  the mechanisms involved in SIT is modulation of  the allergen-
specific immune response from a Th2 dominated response to a Th1 [177] or Treg response 
[178]. Next, the effects on Th cells were evaluated by proliferation of  splenocytes in response 
to rFel d 1 and by measurement of  Th subset specific cytokines. The reduced levels of  IL-5 
in BALF suggested a less potent Th2 profile after SIT. Although not significant, there was a 
tendency for lower proliferation to rFel d 1 and less Th2 cytokines, especially IL-5, in culture 
supernatants of  stimulated splenocytes from rFel d 1:VD3 treated mice than those treated with 
rFel d 1 alone (Fig. 8). Lower proliferation could be due to induction of  Treg by the treatment, 
but IL-10 was not induced in the culture supernatants. This does not exclude the possibility 
that Tregs that act through other mechanisms than IL-10 secretion were induced [187]. These 
results further strengthened the initial findings that covalent coupling of  VD3 to the allergen 
potentiates SIT at lower treatment doses.
Figure 8. Proliferation of  splenocytes from treated mice after stimulation with rFel d 1. Cytokine content in the 
supernatants were measured using cytometric bead array. 
Another effect of  SIT is on humoral immunity, leading to induction of  blocking antibodies, 
mainly of  the IgG4 isotype in humans [184, 186, 188]. Treatment with rFel d 1 and rFel d 1:VD3 
at both doses led to induction of  IgG1 and IgG2 antibodies, antibodies able to block binding of  
human IgE from cat-allergic patients to rFel d 1. It is not surprising that the rFel d 1:VD3 has 
maintained ability to induce blocking antibodies, as only 1/10 of  rFel d 1 was linked to VD3 with 
only one VD3/rFel d 1 coupled, and the rFel d 1 molecules (coupled or not) can be expected to 
have a native folding. Blocking antibodies are thought to have the ability to block binding of  IgE 
to the allergen, thus preventing degranulation of  MCs. Blocking antibodies may also act through 
binding of  the inhibitory FcγRIIB on MCs and basophils [336], thus giving an inhibitory signal 
preventing activation by IgE-mediated cross-linking of  FcεRI.
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This study implies that covalent coupling of  VD3 to an allergen could indeed be beneficial for 
the outcome of  SIT, although we did not investigate if  this mode of  administration was more 
efficient than by co-administration of  allergen and VD3. One problem of  VD3 is that it is 
not water-soluble, which means that aqueous solutions for administration of  vaccines cannot 
be prepared in advance. Covalent coupling of  VD3 to the water-soluble allergen would thus 
simplify the treatment.
4.2 reducInG b- And t- ceLL reActIVItY of feL d 1
Another approach to improve SIT, in particular the safety of  the treatment, is to modify 
the structure of  the allergen to reduce the allergenicity. Several approaches have been tried, 
e.g. by destroying the folding of  the allergen to remove IgE-epitopes by linearization [211], 
multimerisation [218] or by using overlapping peptides [216]. A problem with only reducing IgE-
epitopes is that the T-cell epitopes can still evoke LPR to the treatment. Paper II was focused on 
producing mutated variants of  Fel d 1 by the novel strategy to primarily reduce T-cell reactivity, 
but possibly also the IgE-binding capacity. One problem with SIT is the risk of  inducing local 
and severe side effects. Early phase reactions appear within minutes and are due to the actions of  
MCs and dependent on B cell epitopes, while LPRs appear after several hours and are mediated 
by allergen-specific T-cells. In clinical studies where hypo-allergens with reduced B cell reactivity 
have been used, most adverse events occurred several hours after SIT [219]. Reducing the B and 
T-cell reactivity should thus lead to safer allergens with a lower risk for EAR and LPR in SIT.
Mutations were introduced in Fel d 1 by error prone PCR, and the resulting Fel d 1-mutants were 
selected for by bio-panning to maintain IgE-binding. Maintaining IgE-binding is essential for the 
allergen to keep at least some of  its folding and to prevent the mutations to drive the allergen 
into a completely different protein that would not be recognised at all by T or B cells and thus 
not useful in SIT.
After several rounds of  bio-panning, four final clones were obtained and denoted 3.4.7, 6.7.1, 
6.7.3 and 11.5.2. The clones expressed protein that had preserved protein folding, similar to 
rFel d 1, as shown by CD-spectrometry. The proteins had high helical content, except for 6.7.1 
that differed slightly indicating a somewhat less tight structure. Testing the IgE-binding in a 
direct ELISA also showed reduced IgE-binding for the mutants compared to rFel d 1, except 
for 6.7.1 that had an increased IgE-binding. Probably, the less tight structure of  6.7.1 allows 
easier binding of  IgE and more epitopes might be available for binding. When the mutants were 
tested for IgE-binding in an antigen competition ELISA, at least 50 times higher concentration 
of  Fel d 1-mutant was needed to induce 50% blocking compared with the blocking capacity of  
rFel d 1 (Fig. 9). Reduced IgE-binding indicates that the mutants may be less able to activate 
IgE-mediated effector mechanisms. 
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Figure 9. IgE-binding of  the Fel d 1-mutants in an antigen competition ELISA where a pool of  sera from cat-
allergic patients was incubated with rFel d 1 or Fel d 1-mutants before addition to a rFel d 1-coated ELISA plate.
Further characterisation of  the Fel d 1-mutants showed that the ability to activate basophils 
was lower for the mutants compared to rFel d 1. Generally 3.4.7 seemed to have low basophil 
activation capacity in the patients tested. The patients used in the BAT had different reactivity 
to the allergens tested. This suggests that different mutants could be better for use in SIT 
depending on the patient to be treated and that the composition of  allergen components in the 
mix could be optimised for the individual patients. Proliferation of  PBMCs from cat-allergic 
patients after stimulation with rFel d 1 or the mutants was used to test the T-cell reactivity in 
humans. The mutants 3.4.7 and 6.7.3 stimulated a reduced proliferation response compared to 
rFel d 1 (Fig. 10), indicating a reduced T-cell reactivity. Although other cells of  the PBMCs can 
also proliferate, the results suggest that there is at least no increased cell activation capacity to the 
mutants, independent of  reactive cell type.
Figure 10. Normalised proliferation of  peripheral blood mononuclear cells from cat-allergic patients stimulated 
with rFel d 1 or the different Fel d 1-mutants
A maintained structure of  the allergen is important in order to preserve IgE-binding capacity and 
for the ability to involve B cells in the response, which will facilitate the production of  blocking 
antibodies. As mentioned earlier, induction of  blocking antibodies is a feature of  successful SIT 
[184, 186, 188]. The immunogenicity of  the Fel d 1-mutants was tested in mice, followed by 
evaluation of  IgE blocking capacity of  the anti-Fel d 1 specific antibodies induced. Mice were 
immunised with rFel d 1 or the different mutants and antibody responses were analysed. The IgE-
blocking capacity of  the antibodies was tested after adjusting for titers, as the mutants induced 
more antibodies than rFel d 1. Only the IgG antibodies induced by 11.5.2 had significantly less 
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ability to block binding of  IgE in an inhibition ELISA. When tested for the ability to block 
degranulation in a BAT, 3.4.7 and 6.7.1 showed similar ability as rFel d 1 to block activation. 
Treatment with rFel d 1, 3.4.7 and 6.7.1 in a mouse model for cat allergy was also performed. 
All treatments were able to induce Fel d 1-specific IgG1 and IgG2 antibodies with the ability to 
block IgE-binding. Thus, it seems like the Fel d 1-mutants have characteristics that are beneficial 
for use in SIT, like increased safety due to reduced B- and T-cell reactivity but with maintained 
capacity to induce blocking antibodies. In the future, other parameters important for allergy and 
asthma also need to be investigated in a mouse model.
4.3 AntI-tnf treAtMent of PAtIents wItH Ibd
Inflammatory bowel disease is a complex disease of  unknown aetiology, but it is generally 
considered to result from an inappropriate immune response to commensal bacteria. There is 
evidence of  dysbiosis [263-265], genetic predisposition [270, 274, 277], increased amount of  
IL-17 [259] and increased numbers of  Treg in mucosa [284-288] that seem unable to control the 
inflammation. In paper III, patients treated with anti-TNF antibodies were investigated with 
regards to both Tregs and Th subsets of  PB and the gut mucosa during the first six weeks of  
treatment. Understanding the early events during treatment will improve our knowledge of  the 
therapy and provide information on the mechanisms of  the disease. The indications that T-cells 
are involved in the pathogenesis of  IBD led us to focus on these cells.
In order to detect subsets of  Th cells in fresh blood, we used surface expression of  the chemokine 
receptors CXCR3, CCR4 and CCR6 to identify cell populations that were enriched for Th1, Th2 
and Th17 cells as adopted from Acosta-Rodriguez et al. [60]. In flow cytometric analysis, Th1 were 
gated as CD4+CXCR3+, Th2 cells were gated as CD4+CCR4+CCR6- and Th17 cell were gated 
as CD4+CCR4+CCR6+. The intermediate Th1/Th17 subset that was CXCR3+CCR6+ was 
included in the Th1 gate as these cells express IFNγ [60, 337]. By analysis of  transcription factor 
expression it was found that this gating strategy led to a considerable contamination of  Th2 cells 
in the Th17 subset, probably due to a low number of  Th17 cells. Thus, the Th17 subset could 
not be reliably analysed in this manner, although it could be concluded that there were very few 
Th17 cells in both PB and gut mucosa.
During treatment with anti-TNF, no change in the Th2 subset in PB was detected, and 
there were too few Th2 cells to be reliably detected in gut mucosa. The Th1 cells were more 
abundant and could be detected in both PB and gut mucosa. The percentage of  Th1 cells in 
PB did not change throughout the study. In contrast, the percentage of  Th1 cells in gut mucosa 
increased significantly from week 2 to week 6 (Fig. 11). Th1 cells are important effector cells 
of  inflammation, and thus it was unexpected that they increased, as most of  the patients in 
this study responded to treatment and their inflammation was resolved. Possibly, the induced 
Th1 cells imply that the cause of  the inflammation can be neutralised, in co-operation with 
depletion of  pro-inflammatory TNF.
Figure 11. The percentage of  Th1 cells 
in peripheral blood was analysed as 
CXCR3+ cells of  CD4+ cells.
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Since several studies have suggested that Tregs are induced by anti-TNF treatment [338-340], 
we decided to analyse Tregs and different regulatory mechanisms and if/how they change 
throughout anti-TNF treatment. On the other hand, there are also reports that did not find 
induction of  Tregs by anti-TNF treatment [286, 341]. First, analysis of  CD25, TNFRII, CD69 and 
FOXP3 in PB revealed that neither of  the subsets: CD25+ of  CD4+, CD69+ of  CD4+CD25+, 
CD25+FOXP3+ of  CD4+ or CD25+TNFRII+ of  CD4+, changed throughout the study (Fig. 
12). Though, there was an initial decrease of  CD25+TNFRII+ cells from week 0 to week 2, 
but not from week 0 to week 6. Thus, the number of  Tregs did not change in PB by anti-TNF 
treatment.
Analysis of  the same subsets in the gut mucosa (except FOXP3 staining that could not be 
performed due to low number of  cells) revealed shifts in some of  the subsets. The percentage 
of  CD25+ of  CD4+ T-cells did not significantly change throughout the study, although there 
was an initial decrease followed by an increase of  these cells. Analysis of  CD69 expression, a 
marker of  recent activation, on the CD4+CD25+ cells showed that the percentage of  these cells 
increased during the treatment, suggesting an increase of  activated cells in the gut (Fig. 12). This 
was also in line with the increase of  Th1 cells in the gut mucosa.
Figure 12. Analyses of  regulatory T-cells and recently activated effector T-cells in peripheral blood and gut mucosa.
Interestingly, the percentage of  CD25+TNFRII+ cells decreased in the gut mucosa during anti-
TNF treatment (Fig. 12). This could reflect a decreased expression of  the receptor in the absence 
of  its ligand, but it could also be caused by specific apoptosis of  these cells. It was recently shown 
that addition of  anti-TNF to co-cultures of  CD4+ cells and CD14+ cells from patients with IBD 
induced apoptosis in TNFRII+CD4+ cells [342]. This might be an indication that TNFRII+ 
Tregs present before anti-TNF treatment are not functional and that anti-TNF induces TNFRII-
specific apoptosis of  Tregs, which facilitates the introduction of  functional Tregs. On the other 
hand, it has been shown that there is an increased apoptosis of  CD4+FOXP3+ cells in the 
mucosa of  patients with IBD, and that this apoptosis is reversed by anti-TNF treatment [287]. 
Specific apoptosis of  TNFRII+ Tregs while other Tregs remain functional may be an important 
mechanism of  anti-TNF treatment that needs to be further addressed and investigated in the 
future.
After flow cytometric analysis of  surface and intracellular markers, the functionality of  different 
subsets of  Tregs was investigated in PB. Proliferation of  PBMCs stimulated with commonly 
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encountered antigens (allergens and influenza virus antigens) in the presence or absence of  
different regulatory mechanisms was analysed. Before treatment, blocking of  IL-10 led to 
significantly increased proliferation whereas after treatment with anti-TNF, this increased 
proliferation was not as clear or not even significant. In contrast, when CD25+ cells were removed 
before treatment no significant increase in proliferation was detected. After treatment, there 
was a significant increase in proliferation when CD25+ cells were removed. This observation 
suggests that IL-10 dependent regulation is present during active IBD, but may not be sufficient 
or functional and thus unable to control the inflammation. After blocking TNF, the CD25+ cell 
dependent regulation was more efficient, indicating that this regulatory mechanism is functional 
as most patients responded to treatment. Interestingly, as analysed by suppression proliferation 
assays, there is no difference in the suppressive activity of  CD25+ cells before and after anti-
TNF treatment, but the CD25- cells seem to be more susceptible to CD25+ cell mediated 
suppression after inhibition of  TNF. Indeed, it has been found that effector T-cells are resistant 
to suppression by Treg in type 1 diabetes [343, 344], suggesting that this might be part of  the 
pathogenesis in chronic inflammatory diseases.
The combination of  increased number of  Th1 cells, recently activated Th cells and that CD25- 
cells may be more susceptible to suppression after anti-TNF treatment suggests that the effector 
cells are indeed a target for the treatment. The inflammatory response could become more 
susceptible to attenuation after anti-TNF treatment and this increased suppression seems to be 
facilitated by CD25+ cells.
4.4 HLA-drHI MonocYtes In Ibd
Although T-cells have regulatory and effector roles in the immune system, there are other important 
players. To investigate other mechanisms in IBD, we evaluated the significance of  monocytes, 
presented in paper IV. Monocytes have the ability to migrate to sites of  inflammation when 
activated [17] and to produce pro-inflammatory cytokines [25, 26], but the phenotype of  these 
monocytes is unclear. There are three known subsets of  monocytes, the classical, intermediate 
[19, 20] and pro-inflammatory monocytes [21]. However, there seems to be a higher degree of  
heterogeneity regarding surface antigen expression and functionality than has previously been 
known [345]. Three different IBD treatment groups of  patients were recruited to this study. 
They were treated with GMA, corticosteroids or anti-TNF. Patients receiving GMA or anti-TNF 
could be treated with additional corticosteroids prior to and during the study. A group of  non-
IBD controls was also included.
Initially, the monocytes were analysed for the expression of  CD14, CD16 and HLA-DR. During 
data analysis it was found that the CD14++ monocytes expressing the highest level of  HLA-DR 
were significantly decreased by treatment with GMA and corticosteroids (Fig. 13). There was 
also a significantly higher percentage of  these cells in active IBD than in the control group, but 
treatment reduced the number of  HLA-DRhi monocytes to a level similar to that in the control 
group. Thus, to further analyse these HLA-DRhi monocytes in IBD, subsequent analysis of  
chemokines receptors was performed.
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Figure 13. Percentage of  CD14+HLA-DRhi monocytes in peripheral blood of  patients going through different 
types of  treatment for inflammatory bowel disease.
Interestingly, the patients subjected to anti-TNF treatment did not display a reduction of  the 
HLA-DRhi subset during treatment. Rather, the HLA-DRhi subset was at the same level as the 
control group at treatment initiation, and was slightly, although not significant, increased by 
treatment (Fig. 13). About 50% of  these patients were on a corticosteroid treatment before start 
of  anti-TNF treatment, which may already have reduced the HLA-DRhi population. There was 
also significantly more TNF produced by HLA-DRhi than by HLA-DRlo monocytes. The removal 
of  TNF could lead to induction of  autocrine feed-back mechanisms that activate the HLA-DRhi 
cells and prevent their reduction. This observation could be indicative of  different mechanisms 
being important for the different types of  treatment. The high expression of  TNF by the HLA-
DRhi monocytes also indicated that they are of  a highly pro-inflammatory phenotype.
Our results showed that monocytes in IBD patients have significantly higher level of  CCR9 than 
monocytes from healthy controls (Fig. 14). This result could indicate that CCR9+ monocytes may 
be part of  the pathogenesis in IBD. Further investigation of  the HLA-DRhi monocytes’ surface 
expression of  chemokine receptors revealed differences compared to the CD14+CD16+ and 
CD14++CD16- monocytes, notably in the expression of  the gut homing chemokine receptor 
CCR9. HLA-DRhi monocytes had a higher level of  CCR9 compared to CD14+CD16+ and 
CD14++ monocytes. The ligand for CCR9 is CCL25 [11], which is expressed mainly by thymic 
DCs [346] and mucosal ECs in the small bowel [15]. The specific increase in CCR9 expression 
may also indicate that the HLA-DRhi monocytes have a gut-homing phenotype and are not just 
a generally activated subset.
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Figure 14. Evaluation of  CCR9 expression on monocytes and T-cells in peripheral blood of  patients with 
inflammatory bowel disease and healthy controls.
In order to further elucidate the importance of  the CCR9 expression on HLA-DRhi monocytes, 
mRNA expression of  the ligand CCL25 in gut biopsies was investigated. Preliminary results 
showed that there was expression of  CCL25 mRNA in colonic biopsies during active IBD, but 
the expression was ablated by four weeks of  corticosteroid treatment. Previous studies have not 
detected CCL25 mRNA in the colon of  IBD [347], and there were only three patients included in 
our analysis, which calls for further studies of  CCL25 in colon biopsies of  IBD-patients.
The lower amount of  CCR9 on T-cells as well as monocytes of  healthy controls compared to 
active IBD may reflect that there is less recruitment of  these cells to the gut during homeostasis. 
Inhibition of  the recruitment of  the HLA-DRhi monocytes is probably important for remission 
of  disease as these cells express high levels of  TNF. Thus, this monocyte subset may represent a 
new important target that could be interesting for future treatment of  IBD.
Finding this subset of  HLA-DRhi monocytes and the analysis of  other surface markers in addition 
to CD14 and CD16 highlights the need for more sophisticated ways of  phenotyping monocytes 
in future studies. Indeed, Tallone et al. [345] performed gating on monocytes using the CD14, 
CD16 and HLA-DR together with a variety of  other surface markers to provide more detailed 
information about different subsets. Another study suggests that there are elevated levels of  
CX3CR1
hi monocytes in patients with coronary artery disease [348], indicating that this monocyte 
subset could be an important target in atherosclerosis treatment. Thus, in the future, more detailed 
phenotyping of  monocytes may be needed to thoroughly analyse the involvement of  different 
monocyte subsets in inflammatory disease.
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5 concLusIons
The projects of  this thesis target different inflammatory diseases. The aim was to generate more 
efficient and safer treatments for allergic disease by SIT, which may prevent chronic inflammation 
of  the lungs, and to increase our understanding of  the cellular events when chronic inflammation 
in the gut is resolved. 
Paper I: In this paper we conclude that by covalently linking VD3 to rFel d 1, the efficacy of  
SIT can be improved. The rFel d 1:VD3 was effective in SIT at a lower dose than rFel d 1 alone. 
Improved efficacy means that the safety of  SIT can be improved by using a construct similar to 
this as lower doses of  the allergen can be used, reducing the risk of  severe side effects. Covalent 
coupling of  the VD3 to rFel d 1 should also ensure that the allergen and the immunomodulator 
exert their actions on the same DC. This may lead to the observed increased efficacy, in particular 
for resolving symptoms in the inflamed lung. As the rFel d 1:VD3 preparation most likely has 
correct folding of  rFel d 1, it cannot be expected that the rFel d 1:VD3 should be safer if  used at 
conventional doses. The benefit of  rFel d 1:VD3 is the more efficient immune modulation and the 
possibility to use lower and safer doses in SIT.
Paper II: Here we show that simple error prone PCR and phage display can be used to generate a 
novel type of  allergy vaccine with reduced B- and T-cell reactivity. Despite the reduced reactivity, 
the ability to induce blocking antibodies in mice was only significantly reduced in one of  the four 
investigated Fel d 1-mutants. The reduced reactivity implies that the Fel d 1-mutants are safer to 
use in SIT as the risk for both EPR and LPR are reduced.
Paper III: We conclude that treatment of  IBD patients with anti-TNF leads to an induction of  
Th1 cells in the gut mucosa, at the same time as patients go into remission. Also, the number of  
recently activated Th cells increases in the gut mucosa and CD25- cells become more susceptible 
to suppression by CD25+ cells. The anti-TNF treatment might also have an effect on the type 
of  regulation of  the disease as it seems like IL-10 driven regulation of  antigen-specific immune 
responses is more important in active disease while CD25+ Treg driven regulation is more 
important after attenuation of  inflammation. Interestingly, CD25+TNFRII+ cells are reduced 
by anti-TNF treatment, which may be due to down regulation of  the receptor after neutralisation 
of  the ligand, but may also indicate that induction of  specific apoptosis in TNFRII+ cells is an 
important mechanism of  anti-TNF.
PaperIV: This paper concludes that the subset of  CD14++ monocytes expressing the highest 
levels of  HLA-DR also express the gut homing chemokine receptor CCR9. This subset is elevated 
in patients with active IBD and is reduced when the disease is treated by GMA or corticosteroids. 
The results implicate that this subset is important for the inflammation in IBD. Furthermore, 
different mechanisms seem to be dominant in different stages of  the disease as patients that 
are treated with anti-TNF (about 50% of  those patients are treated with corticosteroids prior to 
anti-TNF, but the dose is often tapered during anti-TNF treatment) display levels of  circulating 
HLA-DRhi monocytes similar to healthy controls. We also show that monocytes may be more 
heterogeneous than the current literature reflects and new multiplex analyses can give higher 
resolved information about the different monocyte populations and their role in inflammation.
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6 future PersPectIVes
In the study of  SIT using rFel d 1:VD3 in the mouse model of  cat allergy, the interesting concept 
of  covalently coupling an immunomodulatory agent directly to the allergen was used. The major 
advantage of  this strategy is that the allergen is delivered to the same APC that is affected by the 
immunomodulatory. Thus the allergen specific T-cell activated by the APC will be specifically 
modulated and this would lead to higher efficiency of  the treatment. Further investigation is 
needed to test how APCs that have ingested rFel d 1:VD3 are affected and what type of  T-cell 
response that is induced. This analysis should preferably be performed on a human DC/T-cell 
co-culture system. Although the results of  our study show that the coupled VD3 is still active and 
is covalently coupled at a 1:10 ratio to rFel d 1, as shown by mass-spectrometric analysis, future 
studies to analyse if  the complete molecule is taken up by APCs would be interesting.
It has also proved that the chemical reaction of  coupling VD3 to rFel d 1 is hard to control and 
to optimise. More stable ways of  connecting the molecules with maintained activity of  VD3 
would be needed in the future. One option could be to link the two molecules to a common 
solid base, e.g. some type of  bead that could also work as an adjuvant. Being a light-sensitive 
hormone, which is not water-soluble, makes VD3 a difficult substance to work with. In the 
future, other immunomodulatory substances may be more interesting to couple to allergen due 
to their more easy handling properties. These could include different types of  carbohydtrate 
adjuvants, immunomodulatory substances from e.g. parasites or endogenous proteins with 
immunomodulatory properties like VIP.
Future studies of  rFel d 1:VD3 in a chronic mouse model of  cat allergy could reveal if  the 
molecule also has the ability to modulate more chronic and neutrophilic inflammation. In such 
a study, flow cytometric evaluation of  Treg and other Th-subsets in PB, spleen and relevant 
lymph nodes should be performed. As such a mouse model shows more features of  allergic 
asthma, e.g. tissue remodelling in the lungs, it will be better suited to evaluate the effects of  rFel 
d 1:VD3 SIT. Currently such a mouse model is being developed by our group. Different routes 
of  administration, e.g. ILIT or epicutaneous could also be investigated for this type of  SIT
In addition, comparison of  rFel d 1:VD3 and co-administration of  rFel d 1 and VD3 should 
be performed. The previous study by Taher et al. [334] showed that co-administration could 
probably be as effective as using a linked molecule. The possibility of  co-administration would 
overcome the difficulties of  linking rFel d 1 and VD3. On the other hand, co-administration 
and covalent coupling of  the immunomodulator may elicit different types of  immune responses 
with different benefits for the allergic response [335]. It is thus of  interest to investigate how the 
covalent linkage affects the response in a comparative study.
The concept of  purposely introducing mutations in the allergen in the study on Fel d 1-mutants 
opens up several possibilities for the future. By using recombinant allergens, component-resolved 
treatment for each patient can be tailored [204]. In the future, customised allergen preparations 
containing only the allergens the patient is allergic to could be preferable in order to design 
an efficient vaccine that does not induce further sensitisations. Comparisons of  allergens with 
disrupted T-cell epitopes with the more common B cell epitope disruption would be interesting 
for assessing efficacy, safety and type of  immune response induced. Any allergen can be mutated 
to be safer, without prior knowledge of  B- or T-cell epitopes using the error prone PCR/Phage 
display strategy. Another possibility that opens up is to combine allergens from different sources. 
Mite group 2 allergens with high similarity were applied in a study combining these strategies, 
producing hypoallergens by DNA shuffling [349]. Recently it was shown in mice sensitised to 
three different allergens that pre-treatment with a multi-allergen-chimera can inhibit development 
of  a Th2 response to all three allergens [230].
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The Fel d 1-mutants should be tested in a mouse model for cat allergy for their ability to affect 
other parameters of  allergy and asthma than the ability to induce allergen-specific blocking 
antibodies. Preferably analysis of  effects on allergic lung symptoms and inflammation should be 
done in a chronic model that better reflects aspects of  human allergic asthma.
In the future, prior to perform clinical studies on allergic patients, promising allergen-mutants 
or allergen linked to immunomodulator need to have been tested on human cells in vitro. A co-
culture system of  MDDCs and naïve Th cells could be used to assess the ability of  the allergens 
to induce Treg and further investigations of  the properties of  those Tregs. Another interesting 
approach for the future is prophylactic allergy-vaccination to prevent the development of  allergy. 
In such a setting, a molecule combined from the major allergens in the specific geographic area 
could be useful. For example, in Sweden cat-, birch- and timothy-allergens could be combined.
The results from the study of  anti-TNF treatment in IBD patients call for further investigation. 
The finding that CD25+TNFRII+ cells are decreased by anti-TNF raises questions about the 
exact mechanism behind the presumed down-regulation of  a specific T-cell phenotype. Obviously, 
one option might be a down-regulation reflecting the absence of  the ligand, but recent reports 
indicate a more intriguing importance of  this receptor. One study indicates increased apoptosis 
of  Tregs in the mucosa of  patients with IBD, which is reversed by anti-TNF [287]. Another 
study suggests that anti-TNF induces apoptosis in vitro in TNFRII-expressing monocytes from 
IBD patients, which could induce apoptosis in CD4+ cells when the cells were co-cultured 
[342]. First of  all it would be interesting to analyse the TNFRII expression on monocyte subsets 
in IBD patients undergoing anti-TNF treatment to evaluate if  there is an effect on these cells. 
Further, analysis of  apoptosis in CD25+TNFRII+ cells and possibly on TNFRII+ monocytes 
during treatment may reveal whether this mechanism is important for the reduced number is also 
of  prime interest. As the TNFRII constitutes one of  the receptors for TNF it is not surprising 
to see the attenuation by anti-TNF treatment. In the future, it could be important to focus on 
TNFRII+ cells as possible treatment targets not only in IBD, but also in other inflammatory 
diseases where TNF is an important mediator. The expression of  this surface receptor might 
also serve as a biomarker for response to anti-TNF-treatment in clinical practice, but larger 
studies are warranted before any clinical application.
Another interesting observation is that effector T-cells may be less responsive to suppression by 
Tregs in active IBD, a state that is changed by anti-TNF treatment. This finding should be more 
carefully investigated on more patients. Interestingly, similar regulation-resistant effector T-cells 
have been found in patients with active type 1 diabetes [343, 344]. Since the study in this thesis 
was not designed to specifically study the functionality of  effector T-cells, future investigation 
of  these cells may be important for the understanding of  IBD. It would be interesting to test the 
anti-TNF effect in vitro. Would effector T-cells from patients with active IBD become responsive 
to regulation if  exposed to anti-TNF in vitro? Would anti-TNF treatment of  effector T-cells from 
healthy donors be affected in a similar way in vitro?
In the study of  IBD patients receiving different treatment modalities, anti-TNF treated patients 
show an initial frequency of  HLA-DRhi monocytes similar to circulating levels in non-IBD 
controls, which may be explained by the fact that many of  the anti-TNF patients have been 
exposed to corticosteroids before initiation. Interestingly, the percentage of  HLA-DRhi monocytes 
seem to slightly increase, although not significantly, during anti-TNF treatment. A separation of  
the anti-TNF group in corticosteroid and non-corticosteroid treated patients may reveal the 
role of  corticosteroids when the corticosteroid dose is tapered during anti-TNF treatment. If  
the numerical up-regulation of  HLA-DRhi monocytes in anti-TNF-treated patients is caused by 
the inhibition of  soluble anti-TNF, such studies could indicate mechanistic differences of  the 
treatment modalities that would be important to take into account when choosing therapy.
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The finding that HLA-DRhi monocytes express CCR9 and high levels of  TNF, in relation to 
the presence of  mRNA for CCL25 in mucosal colon biopsies in patients with active IBD is 
very interesting. Previously, mRNA for CCL25 has only been detected is the small intestine 
[15], and patients with active IBD have been shown not to have CCL25 expression in colonic 
mucosa [347]. Our result could suggest that there is an incorrect expression of  CCL25 in 
IBD, although the finding has to be confirmed in a larger study population. The expression of  
CCR9 in combination with TNF indicates that the HLA-DRhi monocytes are pro-inflammatory 
cells that are recruited to the inflamed mucosa, which may help enforcing the inflammation. 
Migration analyses are needed to investigate if  HLA-DRhi monocytes migrate towards CCL25. 
Our preliminary results indicate that CCR9+ monocytes do migrate towards CCL25, but have 
also revealed the importance of  the two different splicing variants of  CCR9. The CCR9A has 
greater affinity for CCL25 than CCR9B [350]. The CCR9+ monocytes from patients seem to 
have different ability to migrate towards CCL25, which may be due to different expression of  
the CCR9 splicing variants. Further studies of  the expression of  the different variants of  CCR9 
would also be important, possibly for finding future therapy targets.
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7 PoPuLÄrVetensKAPLIG sAMMAnfAttnInG
Immunsystemet är ett komplext nätverk av celler och signalsubstanser som har till uppgift att 
skydda kroppen mot infektioner, läka skadade vävnader och för att förhindra utveckling av cancer. 
Om vi inte hade detta försvar skulle vi inte klara oss i den ogästvänliga värld vi lever i. Ibland 
börjar dock immunsystemet att reagera på ofarliga ämnen i omgivningen (allergen), vilket leder 
till allergier, eller så börjar det rentav attackera den egna kroppen, vilket leder till autoimmunitet.
Den här avhandlingen handlar om behandling av olika sjukdomar där inflammation är ett svårlöst 
problem. Arbete I och II tar upp hur man på olika sätt kan förändra ett allergen som kan användas 
vid allergivaccinering. I arbete III och IV undersöks olika typer av immunceller och vad som 
händer med dessa vid olika typer av behandling av patienter med inflammatorisk tarmsjukdom 
(IBD).
I västvärlden kan så många som 20-30 % av befolkningen vara drabbad av allergiska sjukdomar. 
Den vanligaste formen av allergi är IgE-medierad allergi där antikroppar av typen IgE bildas mot 
allergen. IgE finns på ytan på mastceller och basofiler som är viktiga effektor-celler vid allergi. 
När allergenet kommer in i kroppen binder det till IgE, och när flera IgE-molekyler på samma 
cell binder till samma allergen frisätter mastceller och basofiler ämnen som leder till en allergisk 
reaktion, med allergisk inflammation som följd.
För närvarande finns bara en typ av behandling som långsiktigt förändrar den bakomliggande 
immunologiska orsaken till allergi och det är allergivaccination (SIT). Under allergivaccination byggs 
en tolerans upp mot det allergen man är reagerar mot genom att dosen av allergenet successivt 
ökas. Några problem med SIT är att behandlingen ofta tar lång tid, mellan tre och fem år med 
många läkarbesök, och det finns en risk för allvarliga bieffekter, i värsta fall anafylaktisk chock. 
Därför finns det ett starkt behov att göra allergibehandling med SIT mer effektiv och säker.
I arbete I kopplades det immunomodulatoriska ämnet vitamin D3 (VD3) till det viktigaste 
allergenet från katt (Fel d 1) för att skapa ett mer effektivt allergivaccin till SIT, rFel d 1:VD3. Vi 
valde att använda VD3 på grund av dess förmåga att inducera regulatoriska T-hjälparceller, Treg. 
Detta är en typ av T-cell som kan driva en immunreaktion mot att tåla allergenet i stället för att 
starta en allergisk reaktion. Vi undersökte effekten av rFel d 1:VD3, jämfört med allergenet utan 
VD3 (rFel d 1),  i en musmodell för kattallergi.
Det visade sig att behandling med rFel d 1:VD3 gav bättre effekt än behandling med bara rFel d 1 
när en låg behandlingsdos användes, men att det inte var någon skillnad mellan behandlingarna 
vid en hög behandlingsdos. Framförallt hade rFel d 1:VD3 bättre effekter på de inflammatoriska 
cellerna i lungan och minskade luftvägshyperreaktiviteten, ett kännetecken för astma. Genom att 
undersöka hur mjältceller reagerar på stimulering med rFel d 1 i cellkultur kan man undersöka 
det cellulära immunsvaret efter olika behandlingar. Mjältceller från möss som behandlats med 
rFel d 1:VD3 uppvisade en tendens att reagera mindre på rFel d 1 än mjältceller från möss som 
behandlats med rFel d 1. Båda behandlingarna hade förmåga att inducera antikroppar som kan 
förhindra reaktioner som uppstår med IgE. Sammantaget visade vi i denna studie att rFel d 1:VD3 
skulle kunna vara en kandidat för framtida SIT. Eftersom rFel d 1:VD3 fungerade vid en låg dos 
skulle lägre doser än med rFel d 1 kunna användas vid behandling, vilket skulle öka säkerheten vid 
SIT.
Ett annat sätt att öka säkerheten i SIT kan vara att ändra på delar i allergenet som immunsystemet 
reagerar på (epitoper), vilket gjordes i arbete II. Eftersom T-celler är en viktig del av den allergiska 
reaktionen valde vi att ändra på T-cellsepitoperna i Fel d 1. Detta gjordes genom att genen för 
Fel d 1 förändrades med en metod som ger många mutationer. De muterade Fel d 1-generna 
användes sedan till att producera förändrade Fel d 1-proteiner (mutanter) som fortfarande hade viss 
förmåga att binda IgE-antikroppar. Fyra Fel d 1-mutanter valdes ut och testades för att undersöka 
deras potential för användning i SIT.
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Det visade sig att Fel d 1-mutanterna band sämre till IgE från kattallergiker än rFel d 1 och gav mindre 
reaktioner som beror på IgE. Vita blodkroppar från kattallergiker reagerade även de mindre på 
Fel d 1-mutanterna än på rFel d 1. Efter den lovande karakteriseringen av Fel d 1-mutanternas effekt 
på humana celler från kattallergiska patienter undersöktes även deras effekt i möss. Antikroppar 
från möss som injicerats med Fel d 1-mutanterna hade förmågan att förhindra reaktioner som 
beror på IgE. Sammanfattningsvis verkar strategin att mutera Fel d 1, samtidigt som IgE-bindande 
epitoper behålls, leda till allergen med reducerad reaktivitet och därmed skulle Fel d 1-mutanterna 
kunna vara säkrare än naturligt omuterat Fel d 1 i SIT.
Inflammatorisk tarmsjukdom uppstår troligen när balansen mellan den normala tarmfloran och 
immunsystemet rubbas. Man vet inte exakt varför detta sker, men det finns ett antal teorier, i) 
rubbning av sammansättningen i tarmfloran med andra dominerande bakterier än normalt, ii) 
mikrobiella patogen som invaderar tarmslemhinnan, iii) genetiskt betingad mottaglighet hos 
patienten och iv) otillräcklig reglering av immunsvaret eller ökad aktivering av inflammatoriska 
celler mot tarmfloran. Eftersom orsaken till inflammationen inte försvinner med tiden uppstår en 
kronisk inflammation.
Det finns många olika typer av behandlingar för IBD som har det gemensamt att de på olika sätt 
nedreglerar immunceller. I arbete III undersökte vi patienter under de första veckorna som de fick 
behandling med antikroppar mot tumour necrosis factor α (TNF), som är en signalsubstans som 
stimulerar inflammation. När TNF blockeras dämpas inflammationen, men exakt vad som händer 
med immunsvaret under behandlingen är okänt. Eftersom både Treg celler och effektor T-celler, 
som är aktiva vid inflammation, är involverade i IBD, valde vi att undersöka vad som händer med 
dessa celler under behandling med TNF antikroppar.
Vi upptäckte att andelen effektor T-celler ökade i tarmslemhinnan under behandlingen, vilket var 
oväntat eftersom inflammationen hämmas. Vi kunde inte upptäcka någon förändring av antalet 
Treg, förutom i en undergrupp av Treg som uttrycker en receptor för TNF. Dessa celler minskade 
i tarmslemhinnan under behandling. Vita blodkroppar stimulerades med olika antigen samtidigt 
som olika regulatoriska mekanismer blockerades. Resultatet visade att olika typer av reglering 
verkade innan respektive efter behandling. Vi såg också en tendens till att effektor T-celler var 
mer mottagliga för reglering efter behandling, jämfört med innan. Detta skulle kunna betyda att 
anti-TNF behandling hämmar inflammation genom att motverka Treg celler som inte fungerar, 
samtidigt som fungerande Treg och effektor T-celler som är mottagliga för reglering främjas.
I arbete IV undersökte vi återigen patienter med IBD, men denna gång fokuserades på en annan 
viktig celltyp, monocyter. I studien ingick patienter som genomgick olika typer av behandling 
för IBD. Framförallt upptäckte vi att en typ av monocyter som uttrycker höga nivåer av ett 
protein på cellytan som är nödvändigt för att monocyterna ska kunna aktivera T-celler, HLA-DR 
minskade tydligt när patienter behandlades med kortikosteroider eller granulocyt-monocyt aferes 
(GMA). Denna typ av monocyter (HLA-DRhi) var mycket vanligare i patienter med IBD än hos 
kontrollpatienter. Till skillnad från patienter behandlade med kortikosteroider eller GMA uppvisade 
patienter som behandlades med antikroppar mot TNF en låg nivå av HLA-DRhi monocyter innan 
behandling men de tycktes öka under behandlingen.
Det visade sig även att HLA-DRhi monocyter producerar höga nivåer av TNF och därför skulle 
kunna leda till inflammation. Analys av olika receptorer på olika typer av monocyter visade att HLA-
DRhi monocyter hade ett förhöjt uttryck av en receptor som får dem att förflytta sig från blodet till 
tarmen. Monocyter från patienter med IBD uttryckte i högre grad denna receptor på cellytan än 
monocyter från friska kontroller. Således skulle det kunna vara så att HLA-DRhi monocyter hos 
patienter med aktiv IBD är mer benägna att förflytta sig till tarmen för att delta i inflammationen 
än monocyter hos friska personer.
Avslutningsvis kan konstateras att denna avhandlingen visar att modifierade allergen kan ge en mer 
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effektiv och säker behandling av allergiska patienter än nuvarande allergivaccinationsbehandling. 
Den visar dessutom att olika mekanismer verkar vara verksamma vid olika behandlingar vilket gör 
att valet av behandling av IBD är mycket viktigt.
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